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ABSTRACT
ANALYTICAL METHODS TO SUPPORT DESIGN AND OPTMIZATION OF PROTEIN DRUG
CONJUGATE: FOCUSING ON HAPTOGLOBIN-HEMOGLOBIN COMPLEX AS A DRUG
CARRIER
MAY 2017
SHENGSHENG XU, B.S., WUHAN UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Igor A Kaltashov
Acquired immunodeficiency syndrome (AIDS) remains one of the most serious public
health challenges and a significant cause of mortality for certain populations. Despite the
large number of antiretrovirals (mostly nucleotide and nucleoside analogs) developed in
the past two decades, the inability of small molecule therapeutics to target HIV reservoirs
directly creates a significant obstacle to their effective utilization. Indeed, achieving the
desired therapeutic effect in the absence of the effective targeted delivery must rely on
dosage escalation, which frequently causes severe toxicity. This problem may be solved
by conjugation of antiretroviral agents to endogenous proteins (e.g., hemoglobin
haptoglobin complex) that are specifically recognized by HIV reservoirs (such as
macrophages) for internalization and catabolism. However, conjugation of a large class of
antiretroviral agents (acyclic nucleoside phosphonates, such as adefovir) to a protein is
challenging due to the rapid decay (including hydrolysis and dimerization) of the activated
form of the drug (adefovir phosphonoimidazolide) during transition (ether precipitation)
from organic phase to aqueous phase. This work introduces a novel synthetic strategy
vi

which overcomes the instability of the activated form of adefovir by emulating the first
step of its metabolic pathway (phosphorylation), making it highly reactive towards
primary amine groups of proteins. The effective conjugation of phosphorylated form of
adefovir to protein via an imidazolide based intermediate was demonstrated using
lysozyme as a model carrier protein. Mass spectrometry (MS) based analytical methods
were used to support design and optimization of all those conjugations. Further
optimization of adefovir’s conjugation with hemoglobin (Hb), a drug carrier which targets
macrophage via haptoglobin (Hp)-CD163 mediated heme scavenging system, was
pursued using another novel linker, phosphonoacetate, which allows reactions to be
performed at neutral pH with a satisfactory yield. Successful loading of adefovir to Hp,
the obligatory partner of Hb for targeted drug delivery, via Hb·Hp binding was
demonstrated by MS. Lastly, a new strategy was developed for detecting and quantitating
exogenous Hp·Hb complex with high sensitivity in complex biological samples using
gallium as a tracer of this protein and inductively coupled plasma mass spectrometry (ICP
MS) as a method of detection.
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CHAPTER 1
INTRODUCTION
1.1. Acyclic nucleoside phosphonates
Acyclic nucleoside phosphonates (ANPs) (e.g., adefovir, tenofovir and cidofovir) are
nucleotide analogs which exhibit a broad spectrum of antiviral activities, particularly against
DNA virus and retrovirus [1]. Their active metabolites, diphosphorylated ANPs (ANPpp) act
as strong competitors of DNA polymerase’s normal substrates [e.g., deoxyadenosine-5’triphosphate (dATP) and deoxycytidine-5’-triphosphate (dCTP)] and terminate the
replication of viral DNA. The common structural attribute of those compounds is a
nucleoside attached to an aliphatic chain which contains a phosphonomethyl residue [2].
The methylene bridge between the phosphonate and the rest of nucleoside moiety allows
ANPs to resist 5’-nucleotidase catalyzed dephosphorylation which happens frequently on
monophosphorylated nucleoside analogs and prevents the conversion to their active
metabolites (i.e., nucleoside triphosphate) [3].
1.1.1. Traditional prodrugs of acyclic nucleoside phosphonates
Acyclic nucleoside phosphonates (ANPs) contain phosphonic acid groups which ionize
completely at physiological pH [2]. Those deprotonated compounds become largely
impermeable to mucosal and cellular membrane [2]. Prodrugs enable ANPs to overcome the
physiological barriers during the delivery by enhancing their bioavailability. Briefly, the
phosphonate groups in those nucleotide analogs can be modified by selected protecting
groups to improve ANPs’ lipophilicity, altering drugs’ cell and tissue distribution.
Pivaloyloxymethyl (POM) and isopropyloxymethyl carbonate (POC) are two typical
1

protecting groups used in prodrugs of ANPs (e.g., adefovir dipivoxil [4] and tenofovir
disoproxil [5]). The attachment of POM or POC with those nucleotide analogs can be
performed by using halogeno carbonyloxymethyl derivatives (e.g., POM-Cl/POC-Cl). Those
highly reactive compounds can be attacked by deprotonated ANPs in N, N’dimethylformamide (DMF), producing POM or POC based prodrugs (see Scheme 1.1.) [6].
Despite the improved bioavailability, those protecting groups in the prodrugs of ANPs
undergo rapid degradation during the intestinal transport due to the esterase-mediated
cleavage [7, 8]. For example, POMs in adefovir dipivoxil decompose into pivalic acid and
formaldehyde, releasing free adefovir with lower ability to penetrate cell membrane [7]. As
a result, accumulation of those unprotected drug compounds in kidney causes severe
nephrotoxicity which becomes a critical concern in this prodrug’s clinical trials and eventually
terminates its application in anti-HIV treatment [9]. The proposed pathology for this renal
toxicity is the competition between adefovir’s active metabolites (i.e., adefovir diphosphate)
and deoxynucleoside triphosphate in binding with DNA polymerase γ which is responsible
for replications of mitochondria DNA [1, 10, 11]. POCs in tenofovir disoproxil also undergo
similar degradations, producing unprotected tenofovir, carbon dioxide and formaldehyde
[8]. Although tenofovir disoproxil has relatively lower renal toxicity and was approved by US
food and drug administration (FDA) for anti-HIV therapy, long term oral administration of
this prodrug also leads to patients’ kidney dysfunction [12, 13]. Most recently, an
aryloxyphosphonamidate based prodrug of tenofovir, tenofovir alafenamide, was
approved by FDA for treatment of HIV infection [14, 15]. The daily dose and maximum
concentration in plasma of this prodrug are 25 mg and 16 ng/mL respectively, significantly
2

lower than those of tenofovir disoproxil: 300 mg/d and 250 ng/mL respectively [14].
Therefore, tenofovir alafenamide has great potential to reduce drug’s kidney exposure and
nephrotoxicity in treatment of AIDS. This aryloxyphosphonamidate prodrug is prepared by
a different synthetic strategy. Instead of using chlorinated protecting groups, tenofovir was
activated by thionyl chloride (SOCl2), producing highly reactive phosphonyl chloride which
can be attacked by the phenol and alanine (see Scheme 1.1.) [6].
1.1.2. Next generation of acyclic nucleoside phosphonates’ prodrug: protein drug
conjugate
Although aryloxyphosphonamidate based prodrug reduces tenofovir’s kidney
exposure significantly [14], this type of improvement in drug’s pharmacokinetic profiles
focuses on alteration of compound’s lipophilicity and fails to enable a site specific delivery
which can minimize the toxicity and maximize therapeutic efficacy. Recently, proteinmediated drug delivery has emerged as a promising platform for delivering cytotoxic
agents to cancer cells site-selectively. Monoclonal antibodies are selected as carriers of
those chemotherapeutics because of their recognition by specific receptors on the
membrane of target cells. Until now, two antibody drug conjugates (ADC) (i.e.,
brentuximab vedotin and trastuzumab emtansine) are approved by FDA for cancer therapy
(see details in Figure 1.1.) [16]. This protein-mediated delivery strategy can be also extended
to transport of adefovir/tenofovir to cellular reservoirs of HIV. Haptoglobin [17], one of
the most abundant plasma proteins, is a promising candidate carrier for ANPs’ targeted drug
delivery. The major function of this protein is sequestration of free hemoglobin (Hb) from
circulation to avoid possible renal damage and other negative consequences of intravascular
3

hemolysis [18]. Hb·Hp complexes are processed (catabolized) in macrophages, and their
internalization is triggered by binding to a multi-functional receptor CD163 (Figure 1.2). Since
macrophages and their progenitors (monocytes) play a prominent role in the establishment
of certain types of viral infections (including HIV), virus dissemination, and development of
viral reservoirs [19], an ability to deliver anti-viral therapeutics (e.g., adefovir and tenofovir)
directly to macrophages (e.g., by conjugating them to Hp, Hb or Hb·Hp) should result in a
dramatic improvement of drug efficacy.
As far as we know, ANPs’ conjugation with protein carriers in aqueous solution has not
been investigated even though large numbers of small molecule based prodrugs were
synthesized in organic solvents. Chlorination by thionyl chloride or oxalyl chloride are
frequently used to activate ANP in DMF (see Scheme 1.1.) [6]. The resultant phosphonyl
chloride is highly reactive and undergoes attacks by nucleophiles such as phenol and amino
acids [15]. However, this activation method is not suitable for ANPs’ conjugation in aqueous
solution because both chlorinating agents (i.e., thionyl chloride or oxalyl chloride) and
activated form of ANP (i.e. phosphonyl chloride) undergo severe hydrolysis with the
presence of water. Another synthetic approach uses N, N’-dicyclohexylcarbodiimide (DCC)
to activate ANP, producing phosphonylisourea based intermediate. This type of activation
requires long-term stirring at high temperature (80-100oC) to assure a better yield [6, 20].
That harsh reaction condition probably causes severe aggregation of protein carriers
during the conjugation. Although there are no examples for ANPs’ conjugation in aqueous
solution, activation of ANPs can follow strategies used by nucleoside monophosphate’s
conjugation with proteins. For example, the monophosphorylated form of ribavirin, a
4

nucleoside analog used in treatment of hepatitis C virus infection, was activated by
carbonyldiimidazole

in

DMF

and

its

active

intermediate,

ribavirin

monophosphorimidazolide, was then transferred to aqueous solution to conjugate with
hemoglobin [21].
intermediate

can

Production of this nucleoside monophosphorimidazolide based
be

also

performed

in

water

using

1-ethyl-3-(3-

dimethylaminopropyl)carbodiimide hydrochloride (EDC) and imidazole [22]. These
strategies can be taken into consideration in design of the synthetic protocol for
protein/ANP conjugates.
1.2. Analytical techniques to characterize protein drug conjugate
Conjugation of ANPs randomly targets primary amines on the protein surface. The
formation of covalent bond between drug’s phosphonate and lysine residues probably
eliminates amine’s positive charge and increases negative charges. Those impacts on
protein’s charge patterns vary at different conjugation sites and can be evaluated by ion
exchange chromatography (IXC). The resin of IXC is modified by either anionic (e.g.,
carboxylate and sulfonate) or cationic (e.g., amine) functional groups, allowing the
retention of negatively or positively charged proteins respectively. The elution of protein
analytes can be performed using a buffer with either higher ionic strength or altered pH.
Although IXC enables the separations of protein drug conjugates’ positional isomers
based on their charge patterns, it lacks the ability to obtain more details (e.g., mass) about
those analytes. Mass spectrometry is a powerful analytical technique which provides
sensitive and accurate measurements of ions’ mass-to-charge ratio (m/z) for a variety of
biomolecules including protein drug conjugates [23]. For example, drug to protein ratio
5

(DPR) is an important characteristic of protein drug conjugate, which indicates numbers
of payloads. Determination of this ratio relies on accurate mass measurement performed
by MS [24, 25]. Since the amino acids sequence of protein carrier and reaction mechanism
are well known, expected molecular weights of protein drug conjugates with varying
payloads can be easily calculated, and any mismatches with those theoretical masses
suggest impurities [26]. In addition, DPR is also a pharmacokinetic parameter which
monitors the chemical stability of protein drug conjugates during the delivery. Drug
cleavages which occur in plasma probably cause toxicity and need to be evaluated [27].
1.3. Methods for pharmacokinetic study of protein drug conjugates
Pharmacokinetic (PK) of small molecule medicine and protein therapeutic is one of
the important factors which decide the drug’s clinical success. Protein therapeutics
frequently display unique and unpredictable PK profiles which reflects their differential
susceptibility to proteolysis, renal clearance, and interaction with the host’s immune
system [26]. Protein drug conjugates may exhibit even more complex PK properties due
to their unique molecular structures which incorporate large and small molecule
characteristics [28].
1.3.1. Enzyme linked immunosorbent assay (ELISA)
ELISA is a sensitive method widely used to quantitate both proteins and conjugated
drugs in ADC samples [27]. Briefly, capture reagents (e.g., antigen) immobilized on solid
phase selectively bind with antibodies. Detection reagents, typically horseradish
peroxidase (HRP) conjugated anti-human antibody, are added to associate with those
analytes and to catalyze oxidation reactions on substrates, resulting in colorful or
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fluorescent products for measurement by spectrophotometer [27]. This technique has a
few limitations. For example, the concentration measurements of analytes depend on the
binding properties between analytes and assay reagents, normally 1:1 binding ratio.
Therefore, although this technique can quantitate total antibody and total antibody
conjugated drugs in serum/plasma, it fails to differentiate ADCs with varying drug to
antibody ratios (DARs) and to provide an average DAR, an important PK property which
indicates possible drug release from ADCs in serum/plasma [27]. In addition, this method
is not suitable for quantitation of protein carriers which share sequence with their
endogenous counterparts. For example, ELISA cannot be applied to quantitate
transferrin-CRM107 conjugate due to the abundant interference from endogenous
transferrin [29].
1.3.2. Liquid chromatography mass spectrometry (LC-MS)
MS is a powerful technique widely applied in PK study of protein therapeutics. Since
protein therapeutics in circulation represent a small fraction of the total plasma proteome,
quantitation of those therapeutics using LC-MS requires protein enrichment (e.g.,
immunocapture) to enhance quantitation sensitivity by increasing analytes concentration
and reducing the matrix interference and signal suppression from other proteins in the
sample [26, 30]. For accurate and reliable quantitation of protein therapeutics, an
isotopically labeled protein or peptide needs to be introduced as the internal standard (IS)
to overcome the matrix effect (or ion suppression) during the analysis [31]. IS can be
introduced metabolically during cell culture using isotope-enriched medium (e.g., 13C, 15N)
[32]. This approach effectively avoids errors from downstream sources [33], however,
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expression of protein therapeutics with isotope labels in eukaryotic systems is costly and
labor-intensive [32]. Comparing with the protein-based isotope labeling, introducing
stable isotopes at peptide level during digestion (e.g., enzymatic catalyzed 18O labeling)
becomes a more attractive approach due to its relative ease and universality of labeling
[34]. However, this technique fails to make a distinction between an exogenous protein
and its endogenous counterpart if the degree of structural similarity between them is very
high. An alternative approach to introducing distinct labels to exogenous proteins is to
tag metals on protein surface, making it detectable by inductively coupled plasma (ICP)
MS [35].
1.3.3. Inductively coupled plasma mass spectrometry (ICP-MS)
ICP-MS is a powerful technique widely used for element analysis, which relies on hightemperature plasma that breaks down compounds into atoms and eventually ionizes
them before transfer to a MS analyzer [36]. This technique is recently expanded to
absolute quantitation of protein therapeutics using a metal labeling strategy [36]. Rareearth elements such as lanthanide are frequently used in metal tags to enable sensitive
quantitation of proteins in ICP-MS based analysis due to their high ionization efficiency
and low background (e.g., absence of rare earth element in biological samples and less
polyatomic interferences). For example, metal-coded affinity tag (MeCAT), a lanthanidecontaining reagent which consists of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴tetraacetic acid (DOTA) and cysteine-reactive maleimide group (see Figure 1.2.), was
developed for ICP-MS based quantitation of monoclonal antibody [37]. This metal tag
reagent targets free thiol groups after reducing inter-chain disulfide bonds of antibody,
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thereby impacting less on antibody’s confirmation or binding affinity [37]. In addition to
protein quantitation, ICP-MS is coupled with laser ablation (LA) to allow the
biodistribution analysis of the metal tagged protein therapeutics [36]. This technique uses
laser with high-power to ablate the tissue surface, sweeping sample aerosol into ICP-MS
[36]. It was applied in the analysis of biodistribution of holmium MeCAT tagged anti-HER2
antibody on breast cancer tissues [38].
1.4. Objectives
ANPs are promising nucleotide analogs used in antiretroviral therapy. Their ionizable
phosphonate groups limit drugs’ ability to penetrate cell membrane, resulting in
unsatisfactory pharmacokinetic (PK) profiles [39, 40]. Current strategies to improve ANPs’
PK properties focus on tuning their lipophilicity by derivatization. However, delivery of
those prodrugs is still not site selective and may cause off-target toxicity. Protein
mediated delivery becomes an alternative way to optimize PK parameters of ANP due to
protein’s specific recognition by receptors expressed on membrane of target cells.
Conjugation of ANPs with those protein carriers is desirable to avoid drug’s dissociation
during the transport. However, most of synthetic strategies of ANPs were developed for
aprotic solvent based reaction environment. High temperature, high pH and long-term
stirring are allowed to ensure a better yield. None of those conditions are suitable for
protein. Therefore, it is important to develop novel and robust synthetic strategies to
allow the conjugation to be performed in protein friendly environment such as room
temperature, neutral pH and aqueous solution. The design and optimization of those
synthetic protocols heavily rely on the supports from analytical tools such as
9

chromatography and mass spectrometry. And this work consists of several projects
aiming to use those techniques to assist preparation and characterization of
protein/adefovir conjugates as well as tracing the protein based drug carriers. Specifically,
the objectives of this dissertation include: (i) Overcoming the hydrolytic liability of a
reaction intermediate in production of protein/drug conjugate: conjugation of acyclic
nucleoside phosphonate to a model protein carrier (Chapter 2); (ii) Conjugation of
antiretroviral drug (adefovir) with hemoglobin and loading it to haptoglobin, an obligatory
partner for targeted delivery (Chapter 3); (iii) Evaluation of gallium as a tracer of
exogenous hemoglobin-haptoglobin complex in targeted drug delivery application
(Chapter 4).
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Figure 1.1. Top: brentuximab vedotin (Adcetris®), an anti-CD30 antibody conjugated
with MMAE for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma;
Bottom: trastuzumab emtansine (Kadcyla®), an anti-HER2 (human epidermal growth
hormone receptor 2) antibody conjugated with DM1 for the treatment of HER2+
metastatic breast cancer.
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Figure 1.2. Endosomal routing scenarios encountered by haptoglobin/hemoglobin
complexes in macrophages.
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Figure 1.3. Structure of MeCAT consisting of DOTA which chelates with lanthanide and
maleimide group which targets cysteine.
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Scheme 1.1. Mechanism of conjugation using POM-Cl (top) and activation of adefovir
using thionyl chloride (bottom).

14

CHAPTER 2
OVERCOMING THE HYDROLYTIC LABILITY OF A REACTION INTERMEDIATE IN
PRODUCTION OF PROTEIN/DRUG CONJUGATES: CONJUGATION OF AN ACYCLIC
NUCLEOSIDE PHOSPHONATE TO A MODEL CARRIER PROTEIN
2.1. Introduction
Acquired immunodeficiency syndrome (AIDS) remains one of the world’s most
significant public health challenges and a significant cause of death for certain populations
[41]. Despite the relentless search for a cure of HIV infection, presently antiretroviral therapy
(ART) remains the only feasible therapeutic modality that allows many patients to achieve
and maintain near complete suppression of the virus for extended periods of time [42].
However, the success of ART is undermined by the drug resistance [43], particularly in
pediatric populations [44], placing a premium on the continuous expansion of the repertoire
of available ART agents [45]. Unfortunately, a significant fraction of novel antiretroviral drugs
fail to deliver on their promise, as the inability of small molecule therapeutics to target the
HIV reservoirs creates a significant obstacle to their effective utilization. Indeed, achieving a
desired therapeutic effect in the absence of an effective targeted delivery frequently relies
on dosage escalation, causing severe toxicity. For example, an acyclic nucleotide analog
adefovir [46] that was initially developed as anti-HIV therapeutic failed to gain approval for
that indication due to significant nephrotoxicity, despite having demonstrated a clear
antiretroviral benefit [47]. Pharmacokinetic studies demonstrated that over 98% of
unmodified adefovir molecules are excreted with urine during the 24-hour window
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following an intravenous injection [39], clearly preventing it from reaching anatomical and
cellular viral reservoirs [48].
Far from being unique to adefovir treatment, nephrotoxicity appears to be a common
problem for a number of antiretroviral agents [49-52], imposing significant limitations on
available therapeutic options. The problem of dosage-dependent toxicity can be alleviated
by targeting the ART agents directly to viruses or viral reservoirs [53, 54], and limiting their
levels elsewhere in the organism. One particularly attractive opportunity in this regard is
presented by haptoglobin, and acute phase plasma protein that irreversibly binds free
hemoglobin molecules in circulation and delivers them to macrophages for catabolism [55].
Internalization of the haptoglobin/hemoglobin complexes is mediated by CD163 receptors
that are specific to macrophages and other cells of monocyte lineage[56] that harbor HIV
virus in AIDS patients. The potential of CD163 to serve as a target molecule for cell-directed
therapies has been recognized several years ago [57]. In fact, conjugation of a nucleoside
analog ribavirin to hemoglobin had been explored for targeted delivery to CD163-expressing
cells [58] with the goal of overcoming the dose-dependent toxicity. While this particular
nucleoside analog cannot be used in ART, a strategy can be envisioned where ART agents
are conjugated to haptoglobin/hemoglobin complex to achieve targeted delivery to
macrophages via CD163-mediated internalization to inhibit reverse transcription of HIV in
infected immune cells during early stages of acute infection [3, 59]. A particularly attractive
class of agents includes nucleotide reverse transcriptase inhibitors (NtRTIs) incorporating
structural features such as phosphonate groups that prevent them from being processed by
nucleases [60]. Targeted delivery of such NtRTIs utilizing vehicles capable of traversing
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physiological barriers (e.g., transferrin or anti-transferrin receptor antibodies[61]) can also
solve the problem of poor accessibility of viral pools in the central nervous system, where
cells of monocyte/macrophage lineage (e.g., microglia, perivascular macrophages and
meningeal macrophages) harboring HIV are protected by the blood brain barrier [62, 63].
Conjugation of one of the members of the NtRTI family, cidofovir, to a serine/tyrosine
dipeptide has been recently demonstrated [64-66]. The phosphonate group of cidofovir
readily forms phosphonoester bond with the hydroxyl group of serine in N, N’dimethylformamide (DMF). However, this conjugate undergoes rapid hydrolysis in
aqueous environment at physiological pH with an estimated half-life 0.5-1.4 hours [64,
65], which may not provide an adequate time window for successful delivery of an ART
agent to its target site. Furthermore, most carrier proteins are likely to undergo unfolding
even at relatively low content of organic solvent, causing aggregation and precipitation
during the conjugation process. Therefore, it is highly desirable that the carrier
protein/drug conjugation reactions take place in an aqueous environment under
conditions that do not compromise the higher order structure of the protein. In this
respect, a more attractive scenario would include two steps: chemical activation of the
anti-viral agent in organic solvent followed by the transfer of the chemically active
intermediate to an aqueous protein solution to produce a conjugate. This scheme was
used successfully to produce a ribavirin/hemoglobin conjugate[58] by activating ribavirin
with carbonyldiimidazole (CDI) in DMF to produce a reactive phosphorimidazolide
intermediate. However, our attempts to adopt this strategy to conjugate NtRTIs (such as
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adefovir) to proteins failed due to the extreme instability of the phosphonoimidazolide
intermediate compared to its phosphorimidazolide counterpart.
In this work, a modified conjugation strategy is presented which overcomes the
problem of the phosphonoimidazolide intermediate instability by chemically modifying
adefovir prior to its activation. This initial modification emulates the first step in adefovir’s
metabolic pathway (phosphorylation), allowing a phosphorimidazolide intermediate to
be produced that is reactive towards primary amines (and, to a lesser extent, hydroxyl
groups) on the protein side chains, and at the same time shows remarkable stability visà-vis hydrolytic attacks by water. The new conjugation protocol can be used to attach
adefovir and other structurally related anti-viral agents to proteins recognized by the cell
surface receptors specific to macrophages (such as haptoglobin/hemoglobin complex),
enabling targeted drug delivery directly to the cells harboring HIV viruses.
2.2. Experimental
Materials. Adefovir (9-(2-phosphonomethoxyethyl) adenine, PMEA) was purchased
from AK Scientific, Inc. (Union City, CA). Lysozyme (Lz), 1, 1’-carbonyldiimidazole (CDI),
phosphoric acid (crystalline 99.999% metal trace basis) and imidazole were purchased
from

Sigma-Aldrich

Chemical

dimethylaminopropyl)carbodiimide

Co.

(St.

Louis,

hydrochloride)

was

MO).

EDC

purchased

(1-ethyl-3-(3from

Pierce

Biotechnology (Rockland, IL). Triethylamine (TEA), N, N’-dimethylformamide (DMF) and
anhydrous diethyl ether were purchased from Fisher Scientific (Fair Lawn, NJ). All other
solvents and reagents were of analytical grade or higher.

18

PMEA activation and preparation of conjugates. Preparation of the Lz/PMEA
conjugate is shown in Scheme 2.1., 2.2. and 2.3.. PMEA was converted to PMEA
phosphonoimidazolide (PMEA-Im) using a modification of the previously published
procedure [21]. Briefly, PMEA (15 mg, 0.054 mmol) powder was placed in a 2 mL glass vial.
CDI (0.082 mmol, 1.5 equiv) was dissolved in 400 μL DMF/TEA mixture (3:1, v:v). The
solution was stirred at room temperature for 1.5 hours, followed by addition of 36 μL of
3.1 M solution of anhydrous phosphoric acid (0.054 mmol, 1 equiv) in DMF. The
phosphorylation was performed overnight at room temperature. Afterwards, the
reaction solution was placed to cold diethyl ether to precipitate adefovir monophosphate
(PMEAp). The cloudy diethyl ether was kept at -20 oC for 2 hours followed by
centrifugation, after which the supernatant was decanted. The waxy precipitate at the
bottom was re-dissolved in 100 μL distilled water and divided equally in two parts, which
were mixed with 400 μL 0.2 M imidazole buffer (pH 6.8) and 400 μL 0.2 M sodium
bicarbonate buffer (pH 8.7), respectively. EDC (0.027 mmol, 1 equiv) was added to both
reaction buffers and imidazole (0.027 mmol, 1 equiv) was added to the 0.2 M sodium
bicarbonate buffer. Both reaction solutions were stirred at room temperature for half an
hour. A 50 μL aliquot of the 1 mM lysozyme stock solution was added to each of the
reaction buffers (450 μmol), giving a final protein concentration of 100 μM. The final drugto-protein molar ratio in aqueous solution was around 540:1. Both reaction solutions
were stirred at room temperature for 24 hours.
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Characterization of PMEA derived small molecules. Mass measurements of PMEA
derived small molecules were carried out with a QStar-XL (AB-Sciex, Toronto, Canada)
hybrid quadrupole/time-of-flight mass spectrometer using negative ion mode.
Characterization of the conjugates. Mass measurements of Lz/PMEA conjugates were
carried out with a QStar-XL (AB-Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight
mass spectrometer followed their purification by buffer exchange in 100 mM ammonium
acetate; ions were produced by electrospray ionization (ESI) using a turbospray source.
The conjugates were desalted and denatured via running through C18 column (Waters,
Milford, MA) before an off-line MS based characterization. Fragmentation of conjugate
ions was carried out by selecting a precursor ion (m/z selection window 1627.0 ± 0.4 u)
followed by its collisional activation (50 eV collisional energy). Assessment of the
conjugate heterogeneity (profiling of positional isomers) was carried out by introducing
an online ion-exchange chromatography (IXC) step prior to ESI MS measurements using a
method developed earlier in our laboratory [67, 68]. Briefly, IXC (cation exchange) was
performed on Agilent 1100 (Agilent, Santa Clara, CA) liquid chromatograph equipped with
a 2.1 mm × 100 mm PolyCAT A (PolyLC Inc., Columbia, MD) weak cation-exchange column
(particle size of 5 μm and pore size of 300 Å). Ammonium acetate at pH 7.0 was used for
MS-compatible gradient elution (100 mM in mobile phase A and 1 M mobile phase B).
The flow rate was maintained at 0.1 mL/min, and the linear gradient ran from 0% to 60%
mobile phase B during a 60 min time interval. A Synapt G2Si (Waters, Milford, MA) hybrid
quadrupole/time-of-flight mass spectrometer was used for on-line ESI MS detection.
2.3. Results and discussions
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2.3.1. Preparation of lysozyme/adefovir conjugates.
Our initial attempt to conjugate adefovir to a model protein (lysozyme) using the
procedure designed for conjugating a chemically similar drug ribavirin to hemoglobin [58]
failed to generate any detectable conjugates despite the presence of 7 primary amines
(targets of the conjugation reaction) within the protein. MS analysis of the activated form
of adefovir produced in DMF yielded a mass spectrum with a single peak at m/z 322
(Figure 2.1.) consistent with the notion of the expected product (adefovir
phosphonoimidazolide (PMEA-Im), see Scheme 2.1.) being produced at nearly 100% yield.
However, the conjugation reaction takes place in the aqueous environment, and addition
of even small amount of water to the DMF solution of phosphonoimidazolide (ca. 2.5 %
by volume) resulted in a dramatic alteration of the appearance of the mass spectrum
following a relatively short (15 min) incubation time period (Figure 2.1.). Although the
phosphonoimidazolide ion is still present in the spectrum, the most abundant ionic signal
corresponds to a species at m/z 527; a lower-abundance peak corresponding to
unmodified adefovir (m/z 272) is also present. The mass of ion at m/z 527 is consistent
with the dimeric form of adefovr (linked via pyrophosphonate); this species is formed not
only as a result of exposure to water, but also during diethyl ether precipitation (data not
shown), an essential step required to remove unconsumed reagents and organic solvents
from the chemically activated adefovir prior to its conjugation to a protein.
The re-appearance of the signal of unmodified adefovir (m/z 272) in the mass
spectrum of its activated (phosphonoimidazolide) form exposed to water is likely due to
hydrolysis (Scheme 2.1.) facilitated by formation of the transition zwitterion. Indeed, the
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methylene bridge (-CH2-) in the phosphonoamide moiety exerts an electron donating
inductive effect on both phosphorus and nitrogen atoms, leading to their basicity increase
[69]. As a result, the proton of the hydroxyl group attached to the phosphorus atom is
expected to migrate to the nearby basic nitrogen atom of the imidazole ring, forming a
transition zwitterion and making imidazole a good leaving group [70]. Formation of this
species (with a good leaving group, imidazole) is expected to occur in the
phosphonoimidazolide intermediate, with the imidazole group being rapidly replaced by
water (or another agent capable of a nucleophilic attack) [70]. This behavior is in contrast
to that of phosphorimidazolide which had been demonstrated to be stable to hydrolytic
nucleophilic attacks [71], and is likely due to the high basicity of the phosphorus–linked
nitrogen atom [70].
The hydrolyzed form (i.e. adefovir) of adefovir phosphonoimidazolie (PMEA-Im) is
strongly nucleophilic and can also attack the phosphorus atom in the zwitterionic form of
PMEA-Im, leading to formation of a pyrophosphonate-linked PMEA dimer (Scheme 2.1.),
following essentially the same mechanism as the one proposed for the hydrolytic attack
by a water molecule. The molecular weight of this dimeric product is consistent with the
mass of the most abundant ionic species in the mass spectrum of water-exposed PMEAIm (m/z 527 in Figure 2.1.), lending further credibility to the proposed mechanism.
The anomalous basicity of the nitrogen atom in phosphonoamide bond can be tuned
via a variety of ways, and perhaps the most straightforward approach is to modify αcarbon of phosphorus in PMEA with an electron withdrawing group, such as
trifluoromethyl [70]. However, the structural change caused by this particular
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modification appears to be too significant, and is likely to result in loss of drug’s ability to
bind with HIV’s reverse transcriptase. An alternative approach adopted in this work relies
on extending phosphonate by converting adefovir to adefovir monophosphate, a strategy
informed by the report that nucleoside diphosphorimidazolide is less prone to hydrolysis
than nucleoside monophosphorimidazolide, at least in the case of the adenosine 5’monophosphorimidazolide and 7-methylguanosine 5’-monophosphorimidazolide and
their diphosphorimidzolide counterparts [71]. In order to determine if phosphorylation of
PMEA will make its imidazolide-based intermediate less susceptible to nucleophilic attack,
we first converted PMEA to its monophosphate form (an analog of deoxyadenosine-5’diphosphate (dADP)) to enhance the stability of the reaction intermediate (Scheme 2.2.).
This strategy not only stabilizes the reaction intermediate in aqueous environment
without introducing significant alteration to PMEA structure, but also facilitates
conversion of PMEA to its active metabolite (PMEApp) via bypassing the first
phosphorylation step.
Importantly, replacing imidazole in adefovir phosphonoimidazolide by a chemically
active (primary amine-targeting) group from protein surface should not diminish the
basicity of phosphorus-linked nitrogen in phosphonoamide moiety and stabilize this
linkage [70]. Therefore, PMEA’s conjugation requires efficient linkers to avoid direct
reaction between phosphonate group and primary amine from lysine residues. Here,
PMEA can be phosphorylated to PMEAp (analog of dADP) [71]. The basicity of nitrogen in
phosphoramide moiety of PMEA monophosphorimidazolide (PMEAp-Im) can be
efficiently reduced because the introduced oxygen at α-position of terminal phosphorus
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inductively withdraws electrons from nitrogen [69]. Therefore, the formation of transition
zwitterion can be inhibited and the intermediate is stabilized. The phosphorylation was
carried out adding anhydrous phosphoric acid DMF solution in PMEA-Im. The ESI mass
spectrum of reaction mixture acquired at negative ion mode indicates that the major
product (i.e. PMEAp m/z=352.2) coexists with hydrolytic product and diphosphorylated
product (i.e. PMEApp m/z=432.2) (see Figure 2.1.). To reduce loss of efficient component
(PMEAp) during the transfer from DMF to water, PMEAp was directly precipitated in cold
diethyl ether rather than activated by CDI again in DMF. The major advantage of this step
is that PMEAp has lower solubility in cold diethyl ether (non-polar solvent) than PMEApIm, due to its relative higher polarity.
The phosphorylated form of adefovir (PMEAp) extracted from DMF was redissolved
in 50 mM pH 6.8 imidazole-HCl aqueous buffer, followed by addition of EDC to induce
activation. This reaction produces an O-acylisourea intermediate, which is known to be
rapidly attacked by imidazole groups [22], a trait that was exploited in our work to
conjugate PMEA to a protein (Scheme 2.3.). The “on-demand” formation of PMEAp-Im in
the presence of the protein greatly reduces non-productive reaction channels (e.g.,
hydrolysis of this intermediate by water molecules), while allowing the nucleophilic
attacks by the primary amines (lysine side chains) to take place, leading to the conjugate
formation. While the unconsumed EDC is usually quenched prior to mixing with protein
solutions with 2-mercaptoethanol, we chose to avoid this step, as the presence of this
reagent in the protein solution would almost certainly induce reduction and/or
rearrangement (scrambling) of disulfide bonds. The downside of keeping EDC in solution
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is the occurrence of side reactions, although they can be suppressed by selecting
appropriate reaction conditions (vide infra).
2.3.2. Characterization of the lysozyme/adefovir conjugates.
ESI mass spectra of Lz/PMEA conjugates prepared at pH 6.8 and pH 8.7 are shown in
Figure 2.2.. The ionic species present in each mass spectrum display narrow charge state
distributions, and the average extent of multiple charging is consistent with compact
(natively oxidized) conformations in solution [72]. Both spectra contain signals of intact
(unmodified) Lz and a 1:1 conjugate. In addition, the mass spectrum of the conjugate
produced under mildly basic (pH 8.7) conditions contains ionic signals corresponding to
conjugates with 2:1 stoichiometry, as well as a range of other products. The mass analysis
of these modified Lz species reveals two types of chemical modification (addition of 71.1
and 128.2 Da, consistent with reactions of residual EDC with the protein molecule[20]),
as well as their combinations with each other and with PMEA/Lz conjugates. Specifically,
modification of carboxylic groups of aspartic and/or glutamic acid residues is likely to give
rise to unstable O-acylisourea intermediates, which are then converted to stable Nacylurea products via the intramolecular O-to-N acyl rearrangement in the presence of
excess EDC[73] (see Scheme 2.4.). No dead-end products are observed in the mass
spectrum of Lz/PMEA conjugate produced at pH 6.8, indicating that the unstable Oacylisourea intermediates undergo quick hydrolysis prior to acyl rearrangement at neutral
pH. Therefore, even though both the conjugation reaction yield and the average drug
loading are noticeably lower when the reaction is carried out at neutral pH, these
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conditions are still preferable to mildly basic pH, as the products are much less
heterogeneous.
2.3.3. Further evaluation of heterogeneity of lysozyme/adefovir conjugates using
online ion exchange chromatography mass spectrometry (IEC/MS).
Although the mass spectrum of Lz/PMEA conjugates produced at neutral pH reveals
only a single species (in addition to the intact unmodified protein), the sample may
contain several isobaric species that differ from each other by the location of the
conjugation site. In order to evaluate the structural heterogeneity of this sample with
respect to the possible presence of several positional isomers, it was analyzed by ion
exchange chromatography with on-line detection by ESI MS. This technique was recently
developed in our laboratory [67] and successfully applied for characterization of samples
as complex as PEGylated glycoproteins subjected to stress conditions [68]. Both total ion
and UV absorption chromatograms (UV data is shown in Appendix F) of the Lz/PMEA
conjugates show a series of peaks, and the on-line MS detection provides evidence that
all species eluting before 55 minutes have masses consistent with 1:1 conjugation
stoichiometry (Figure 2.3.). Integration of the intensities of the Lz/PMEA conjugates’
peaks in UV absorption chromatogram suggests that the yield of the conjugation reaction
is 23%, which is reasonably close compared to the 27% yield obtained by integrating ion
peaks in the mass spectrum of the reaction mixture (Figure 2.2.).
PMEAp conjugation to the protein at the lysine side chain not only eliminates the
positive charges on the ε-amine group of this residue, but also introduces negative
charges (phosphonate and phosphate groups of PMEAp). Although the total number of
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charges is the same for all isomers, the unique position of the PMEAp group on the surface
of the protein will have a profound effect on the surface charge density pattern. The
charge density is an important determinant of the protein retention on the ion exchange
resin [74]; therefore, it should not be surprising that IXC allow a number of isomeric
conjugates to be resolved (Figure 2.3). What is surprising, however, is the fact that the
number of resolved isobaric conjugates exceeds the total number of amines (six ε-amines
at lysine side chains and one α-amine at the N-terminus of the protein). One plausible
explanation for the large number of the observed isobaric species could be the occurrence
of protein deamidation during the conjugation process. Deamidation is a common nonenzymatic post-translational modification (PTM), which frequently (and inadvertently)
occurs during a variety of protein handling steps [75], making it a serious nuisance in
biopharmaceutical analysis. Deamidation results in a mass increase of only 1 Da, which is
nearly impossible to detect when the protein mass is large; however, in our case a onemass unit shift in isotopic distributions of the Lz/PMEA conjugate should be readily
detected because of the relatively low mass of the latter. No such shift was detected for
either of the species eluting prior to 55 min. in IXC shown in Figure 2.3, suggesting that
deamidation does not take place under the conditions chosen to produce the conjugates
(pH 6.8).
In order to understand what could have contributed to the unexpectedly large
number of isomeric 1:1 Lz/PMEA conjugates, collisionally activated dissociation (CAD) of
the mass-selected Lz/PMEA ions was carried out and the mass spectra of the resulting
fragments (Figure 2.4.) was analyzed. CAD of the Lz/PMEA ion at +9 charge state (m/z
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1627.6) gives rise to a relatively small number of fragment ions. Singly charged fragment
ions are observed in the low-m/z region of the mass spectrum (m/z 274 and 354) and
their complementary fragments at high m/z region (m/z 1597.3, 1786.8 and 1796.8). The
most abundant of the two low-mass fragments (m/z 274) corresponds to a (PMEA+H)+,
produced by the cleavage of P-O bond in the phosphate group of the conjugate. The
complementary ion gives is represented in the CAD mass spectrum with an abundant
peak at m/z 1797 (charge state +8), and a fragment ion with the same mass but different
charge state (+9) is observed at m/z 1597 (corresponding to the neutral loss of PMEA from
the precursor ion). The presence of these fragment ions in the CAD mass spectrum of the
Lz/PMEA conjugate is not surprising, since the phosphoester bonds are known to be labile
in the gas phase and undergo dissociation prior to the cleavage of the polypeptide amide
bonds [76]. What is surprising, however, is the presence of the second low-m/z peak in
the CAD mass spectrum (a singly charged species at m/z 354). This mass corresponds to a
(PMEAp+H)+ ion, which can only be produced upon fragmentation of the Lz/PMEA
conjugate if PMEAp is attached to the protein via hydroxyl-bearing side chain, such as
serine or threonine, as opposed to a “conventional” linkage via the amino group of lysine
side chains and the polypeptide N-terminus. Phosphoserine peptides are known to
undergo fragmentation upon collisional activation to lose 98 Da mass (equivalent to a
phosphoric acid compound) and to produce dehydroalanine via β-elimination [76]. Gas
phase fragmentation of serine linked PMEAp probably follows the same mechanism,
producing a singly charged PMEAp.
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The existence of the PMEAp/protein conjugates where the pro-drug is linked to the
polypeptide chain via side chains with hydroxyl-group not only explains the appearance
of the CAD spectrum (Figure 2.4.), but also accounts for the anomalously high number of
chromatographic peaks in the XIC for the 1:1 conjugate, which exceeds the number of
primary amine groups in the protein (Figure 2.3.). In retrospect, conjugation at Ser (and
possibly Thr) residues using the amine-targeting chemistry presented in this work may
not be that surprising, because their side chains become nucleophilic upon deprotonation
which is induced by surrounding basic residues (e.g., lysine and arginine) and is probably
solution pH independent, while neutral pH limits the fraction of primary amine that can
participate in the attack of activated form of PMEAp. From the practical standpoint, the
ability of hydroxyl groups to compete with primary amines as conjugation sites may
actually prove beneficial vis-à-vis designing affective means of targeted delivery to
macrophages, as no solvent accessible Ser and Thr residues of haptoglobin are known to
participate in binding to either hemoglobin or CD163 (the cell-surface receptor that
enables internalization of the Hp/Hb complexes by macrophages) via hydrogen bonding
or Van der Waals interaction, while 5 Lys residues (K262, K291, K297, K345 and K379) are
known to participate in such interactions [77-81].
The significant degree of structural heterogeneity of the 1:1 PMEAp/protein
conjugate produced in this work using a model protein provides important lessons vis-àvis production of adefovir conjugates with real carrier proteins (such as hemoglobin or
haptoglobin). Indeed, a very large fraction of hemoglobin (αβ dimer) and haptoglobin
surface (14 % and 13 %, respectively) are localized within the binding interface when the
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hemoglobin/haptoglobin complex is formed (the surface area buried at the interface was
calculated by subtracting the sum of solvent accessible areas of each protein component
alone from that for the complex and dividing the result by two, crystal structure of human
hemoglobin/haptoglobin complex (pdb: 4X0L) was used for the calculation of buried area).
These interface regions incorporate 6 residues (i.e., K291, K297, K345 and K379 on Hp; V1
and K99 on Hb(α)) whose side chains or N-terminal are targeted by the conjugation
reaction, which include 11% of all surface primary amines. In addition, some Ser or Thr
residues located in these binding areas might undergo deprotonation and become
nucleophilic, and the participation of those residues in conjugation largely depends on
their solvent accessibility and local electrostatic environment. Since neither hemoglobin
nor haptoglobin alone can effectively interact with the CD163 receptor (a critical step in
internalization of these proteins by macrophages), it appears that covalent attachment of
PMEAp to any of these side chains will have a strong negative impact on the effectiveness
of

targeted

delivery

by

compromising

the

integrity/stability

of

the

hemoglobin/haptoglobin complex. In the absence of the effective chemical means to
direct the conjugation reaction away from these critical sites, it would seem prudent to
produce the conjugates using the hemoglobin/haptoglobin complex as a starting material,
instead of either hemoglobin or haptoglobin alone. Formation of a stable complex prior
to the conjugation procedure will shield the critical Lys, Ser and Thr side chains from the
adefovir monophosphorimidazolide. In the absence of such “natural” protection during
the conjugation step, due care should be exercised to ensure the ability of the conjugates
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to associate with the physiological partner thereby enabling the receptor recognition and
conjugate internalization by the targeted cells.
2.4.Conclusions
In this work, we introduced a robust synthetic strategy to overcome the instability of
adefovir phosphonoimidazolide by emulating the first step (i.e. phosphorylation) of
adefovir metabolic pathway and used this strategy to demonstrate successful conjugation
of this anti-viral drug with a model protein. The phosphorylation of adefovir allows the
conversion of α-position functional group of terminal phosphorus from methylene (-CH2-)
to oxygen, altering the electron density of phosphorus linked nitrogen and reducing its
basicity in imidazolide based intermediate. This modification efficiently inhibits the
migration of proton from phosphorus to its adjacent nitrogen and a formation of
transition zwitterion, which frequently occurs in phosphonoimidazolide based
intermediates and causes their hydrolytic instability. Mass spectrometry was used to
monitor the outcomes of individual steps in the adefovir’s activation, allowing us to
understand why the classical conjugation chemistry failed in this drug. Use of mass
spectrometry was also critical in selecting the optimal conditions for the coupling of
adefovir monophosphate to the model protein, as the conditions favoring higher
conjugation yield (and higher drug-to-protein loading ratio) were shown to also lead to
formation to a large amount of dead-end (hydrolyzed) cross-links and mixed products. A
reasonable compromise between modest conjugation yields (27%) and product purity
(almost exclusively 1:1 conjugate) was found; however, the conjugate was shown to
exhibit significant structural micro-heterogeneity due to distribution of the conjugation
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sites among 12 protein site chains. This exceeds the number of primary amines (the
intended targets of the conjugation reaction), suggesting involvement of other group(s)
in conjugation. Fragmentation patterns of the conjugates activated by collisions in the gas
phase provide unequivocal evidence that primary alcohols (side chains of Ser and Thr)
also participate in conjugation reactions. The novel synthetic strategy developed in this
work can be applied to other anti-viral drugs (such as tenofovir, which exhibits a structural
template similar to adefovir, including the presence of a phosphonate group, as well as
other members of acyclic nucleoside phosphonate family). A work is currently underway
in our laboratory to apply the new synthetic strategy to conjugate adefovir to a
hemoglobin/haptoglobin complex, enabling targeted delivery of this drug directly to
cellular reservoirs of HIV.
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Figure 2.1. Mass spectra of PMEA-Im in DMF (brown) and DMF/water (blue) and
PMEAp in DMF (black) acquired at negative ion mode. Ion peaks: m/z 322, 527, 272,
352 and 432 represent PMEA-Im, PMEA dimer, PMEA, PMEAp and PMEApp
respectively.
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Figure 2.2. ESI mass spectra of the products of Lz conjugation with PMEAp carried out
at pH 8.7 (red trace) and 6.8 (blue trace). The inset shows a zoomed view of ions with
charge state +9: the base peak at m/z 1590.4 corresponds to intact Lz; mass shift of
335 Da corresponds to conjugation of a single PMEAp to the protein, while additions
of 71, 128 and 199 Da represent Lz’s N-acyl-N-3-ethyl carbamic acid derivative, N-acylN-3-dimethylaminopropyl carbamic acid derivative and their combination respectively
(see Scheme 2.4. for more structural details).
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Figure 2.3. Total ion chromatogram (black trace) of Lz/PMEA conjugate produced at
pH 6.8 and extracted ion chromatograms for the unmodified protein (blue), 1:1
conjugate (purple) and 2:1 conjugate (red) plotted with different magnification factors
(the m/z values indicate the ions selected for plotting each XIC). The inset shows
zoomed views of ion peaks at charge state +8 from the mass spectra averaged across
the elution windows as indicated on the panel (peaks labeled with stars correspond to
sodium adducts).
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Figure 2.4. Mass spectrum of fragment ions produced by collisional activation of 1:1
Lz/PMEA conjugate (m/z 1627.6). The diagrams in the inset show structure of observed
fragment ions (fragments that can originate from precursors where PMEAp is
conjugated either to primary amines or alcohol hydroxyls are labeled in red, while the
fragments that can originate exclusively from precursors where PMEAp is conjugated
to alcohol hydroxyls are labeled in blue).
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Scheme 2.1. Mechanisms of PMEA activation with CDI (top), formation of PMEA-Im
transition zwitterion and hydrolysis (middle) and formation of PMEA dimer (bottom).
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Scheme 2.2. Mechanism of phosphorylation of PMEA.
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Scheme 2.3. Mechanisms of activation of PMEAp with EDC in aqueous solution (top)
and the conjugation of PMEAp with primary amine (middle) and hydroxyl groups
(bottom).
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Scheme 2.4. Mechanisms of formation of N-acyl-N-3-dimethylaminopropyl carbamic
acid (NDCA) and N-acyl-N-3-ethyl carbamic acid (NECA).
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CHAPTER 3
CONJUGATION OF ANTIRETROVIRAL DRUG (ADEFOVIR) WITH HEMOGLOBIN AND
LOADING IT TO HAPTOGLOBIN, AN OBLIGATORY PARTNER FOR TARGETED DRUG
DELIVERY
3.1. Introduction
Adefovir, namely 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA), is a promising
antiretroviral drug which was developed for anti-HIV therapy [3]. Its active metabolite,
adefovir diphosphate [PMEApp, analog of deoxyadenosine-5’-triphosphate (dATP)], is able
to incorporate with HIV’s reverse transcriptase and terminate the viral complementary
DNA’s replication [82]. To increase the bioavailability of this drug, two pivaloyloxymethyl
(POM) groups are conjugated with PMEA’s phosphonate via phosphonoester bonds to
produce its prodrug adefovir dipivoxil [bis(pivaloyloxymethyl)-PMEA, bis(POM)-PMEA].
However, clinical trials of this prodrug in treating HIV infected patients were discontinued
due to kidney toxicity [12, 83]. Although POM facilitates PMEA’s intestinal transport, it
undergoes rapid chemical and enzymatic degradation during this process as well as in
plasma, resulting in PMEA and mono(POM)-PMEA with reduced cell permeability [7, 84].
Those hydrolytic products of bis(POM)-PMEA accumulate in kidney via renal clearance
instead of reaching therapeutic targets, causing nephrotoxicity. Alternatively, POM was
replaced by 1-aryl-1,3,-propanyl in a PMEA’s prodrug called pradefovir to increase the liver
accumulation and to reduce kidney exposure of PMEA in treatment for another viral
infection [i.e. hepatitis B virus (HBV)] [85]. This prodrug maintains high stability in plasma
because it can be only cleaved by liver specific enzyme [85]. However, the clinical trials of
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pradefovir in anti-HBV treatment was terminated owing to adverse results in non-clinical
carcinogenicity studies [86]. Alkoxyalkyl monoesters such as hexadecyloxypropyl (HDP)
are another type of protecting groups for drugs to increase their intracellular
concentration taking advantages of lipid uptake pathway [87]. Conjugation of HDP with
PMEA was demonstrated to improve PMEA’s efficacy against HIV [87, 88]. However, HDPPMEA was found to have much lower half maximum cytotoxic concentration (CC50): 60
nM than that of PMEA (CC50: 157 µM), indicating a significant increase of toxicity after the
conjugation [88].
Protein mediated targeted delivery has great potential to improve the site-selectivity of
PMEA’s transport in vivo. Conjugation of PMEA with a model protein carrier, lysozyme, has
been recently accomplished using a phosphate linker (see Chapter 2). In this synthetic
strategy, phosphorylation of PMEA overcomes the instability of the activated form of
PMEA (adefovir phosphonoimidazolide, PMEA-Im), making it reactive towards primary
amine groups on protein. However, this conjugation requires long term stirring (more
than 24 hrs) and basic reaction pH (pH 8.7) which probably introduce a risk of protein
aggregation and post-translational modifications (e.g., deamidation), causing loss of
material and safety issues in drug application [89]. In this work, we developed a novel
phosphonoacetate linker for PMEA’s conjugation with protein carrier. This new strategy
was applied on hemoglobin (Hb), a promising drug carrier which binds haptoglobin (Hp)
with high affinity and targets macrophage via CD163 mediated endocytosis [21]. This linker
allows effective conjugation of PMEA with protein to be performed under neutral pH and
with significant reduced reaction time. Although a few byproducts are introduced in this
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reaction, Hb/PMEA conjugates remain the main species. The successful loading of PMEA on
Hp∙Hb complex via Hp and Hb’ association indicates that these conjugates are suitable for
further evaluation of their cellular uptake and bioactivity.
3.2. Experimental
Materials. Adefovir was purchased from AK Scientific, Inc. (Union City, CA). 1,1’carbonyldiimidazole (CDI), phosphonoacetic acid (PA), dithiothreitol (DTT) and human
hemoglobin were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO). Nhydroxysulfosuccinimide (Sulfo-NHS), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride (EDC) were purchased from Pierce Biotechnology (Rockland, IL).
Triethylamine (TEA), trifluoroacetic acid (TFA), formic acid, N, N’-dimethylformamide
(DMF), anhydrous diethyl ether and acetonitrile were purchased from Fisher Scientific
(Fair Lawn, NJ). Human haptoglobin phenotype 1-1 (Hp) was purchased from Athens
Research & Technology (Athens, GA).
Synthesis

of

adefovir

phosphonoacetate

(PMEApa)

and

preparation

of

hemoglobin/adefovir conjugates (Hb/PMEA conjugates). The scheme for preparation of
Hb/PMEA conjugates is shown in Scheme 3.1.. Adefovir was converted to adefovir
phosphonoacetate (PMEApa) based on the modified protocol used in adefovir’s
phosphorylation (see Scheme 2.1. and 2.2.). Briefly, adefovir (10 mg, 0.036 mmol) was
placed in a 2 mL glass vial, followed by addition of 300 μL 0.24 M CDI (0.072 mmol, 2 equiv)
solution which contains 75% (v/v) DMF and 25% (v/v) TEA. The cloudy reaction mixture
was stirred at room temperature until it becomes clear. 10 mg (0.072 mmol, 2 equiv)
phosphonoacetic acid powder was added to this solution and the mixture was stirred at
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room temperature overnight. Afterwards, the reaction solution was placed in cold diethyl
ether to precipitate PMEApa. The cloudy diethyl ether was kept at -20 oC for 2 hours prior
to centrifugation. The white precipitates at the bottom of the centrifuge tube were redissolved into 300 μL 0.2 M phosphate buffer (pH 7.5), followed by addition of EDC (0.11
mmol, 1.5 equiv) and sulfo-NHS (0.11 mmol, 1.5 equiv) and stirring at room temperature
for 20 min. 2 µL 500 mM DTT was added in solution to quench extra EDC before mixing
with 700 µL 5.3 mg/mL Hb solution (0.2 M phosphate buffer, pH 7.5). The concentration
of Hb and PMEApa to Hb ratio were calculated to be 3.7 mg/mL [equivalent to 57 µM Hb]
and 500:1 respectively. The reaction solution was stirred for 30 min prior to addition of 2
µL 1 M glycine to quench unreacted sulfo-NHS ester based compounds. The quenching
step lasted 20 min.
Liquid chromatography mass spectrometry (LC/MS) based characterization of
Hb/PMEA conjugates. The reaction mixtures were analyzed with reverse phase LC/MS
using an Agilent 1100 HPLC (Agilent, Santa Clara, CA) coupled with a Bruker SolariX 7.0T
Fourier transform ion cyclotron resonance mass spectrometer (Bruker Daltonics, Billerica,
MA). Hb (α)/PMEA conjugates and Hb (β)/PMEA conjugates were separated using a Waters
BioSuiteTM C18 column (100Å, 3 µm, 2.1×50 mm) at a flow rate of 0.25 mL/min with the
elution shown in Table 3.1.. Mobile phase A and B were water and acetonitrile
respectively, containing 0.1% formic acid and 0.02% TFA. The UV absorbance was
measured at 280 nm.
Native electrospray mass spectrometry (native ESI-MS) based characterization of
Hp ∙ Hb/PMEA conjugates complex. Off-line native ESI-MS analysis of Hp ∙ Hb/PMEA
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conjugates complex was carried out using a QStar-XL (AB-Sciex, Toronto, Canada) hybrid
quadrupole/time-of-flight mass spectrometer equipped with a nanospray source. The
desalted Hb/PMEA conjugates were incubated with human Hp (4:1 molar ratio) at 4oC for
2 hours. Afterwards, Hp∙Hb/PMEA conjugates complex was isolated by Agilent 1100 HPLC
(Agilent, Santa Clara, CA) equipped with a TSKgel G3000SWxl size exclusion column
(Tosoh, Tokyo, Japan). The separation was performed using 150 mM ammonium acetate
solution as mobile phase at a flow rate of 0.8 mL/min. The UV absorbance was measured
at 280 nm.
3.3.Results and discussions
3.3.1. Preparation of hemoglobin/adefovir conjugates.
A phosphate linker had been previously reported to enable PMEA’s conjugation with
a model protein carrier, lysozyme (see Chapter 2). Phosphorylation of PMEA allows the
formation of stable phosphoramide bond with primary amine groups from protein
surface. However, this reaction using phosphorimidazolide based intermediates (i.e. the
activated form of adefovir monophosphate: adefovir monophosphorimidazolide)
requires long term stirring and basic pH to assure a better yield (see Chapter 2). Stirring
Hb for a few days probably introduces a risk of aggregation and precipitation during the
conjugation due to its lack of disulfide bonds to maintain compact conformation. We
selected phosphonoacetate as a linker to improve the reaction efficiency of protein PMEA
conjugation. The advantage of this linker is that it provides not only phosphonate which
acts as strong nucleophile to attack adefovir phosphonoimidazolide (PMEA-Im, the
activated form of adefovir) but also carboxylate group which targets primary amine
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groups with the activation by EDC/sulfo-NHS [20]. Compared to phosphorimidazolide
based reaction intermediates frequently used in nucleotide’s bioconjugation, sulfo-NHS
ester intermediates have much higher efficiency in amide bond formation [20-22]. The
ESI mass spectrum of reaction mixture (after addition of phosphonoacetate) acquired in
negative ion mode indicates the production of adefovir phosphonoacetate (measured
m/z equals 394.0, very close to calculated m/z of PMEApa: 394.03) (see Figure 3.1.).
PMEApa was then activated by EDC/sulfo-NHS to conjugate with Hb in 0.2 M phosphate
buffer, pH 7.5 [20].
3.3.2. Characterization of hemoglobin/adefovir conjugates.
Sulfo-NHS esters of PMEApa form amide bonds with primary amine groups from
solvent accessible lysine residues/N-terminus on Hb effectively. Each conjugation of
PMEApa will result in 377.19 Da mass addition on either Hb α-chain or β-chain. Since
PMEApa compounds are not purified prior to mixing with Hb (CDI, DMF and TEA are
removed by ether precipitation), some impurities originated from its production might
induce side reactions during the conjugation with Hb. PMEA and PMEA dimer are probably
two small molecule byproducts which coexist with PMEApa after ether precipitation.
However, neither of them is able to participate in the reaction with Hb because PMEA cannot
form stable phosphonoamide bond with primary amine group and PMEA dimer has strong
steric hindrance which prevents it being activated by EDC/sulfo-NHS [70]. Excess
phosphonoacetate added to ensure high yield of PMEApa’s production might be a concern
about introducing protein byproducts because this compound contains carboxylate group
which can be activated by EDC/sulfo-NHS. The mass addition on Hb caused by
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phosphonoacetate conjugation is calculated to be 122.02 Da. Reverse phase LC/MS was
used to characterize hemoglobin α-chain PMEA conjugates [Hb (α)/PMEA conjugates] and
hemoglobin β-chain PMEA conjugates [Hb (β)/PMEA conjugates]. ESI mass spectrum
averaged from 29.8 min to 37.8 min (see Figure 3.2.) indicates that it consists of Hb (α)/PMEA
conjugates and very few Hb (β)/PMEA conjugates (see Figure 3.3.). The most abundant peak
(m/z 862.24 charge state 18+) in this mass spectrum indicates a mass shift 376.92 Da on Hb
(α) (calculated mass addition 377.19 Da), corresponding to Hb (α)/PMEA conjugates with 1:1
drug to protein ratio (DPR) (see Table 3.2.). The calculation of Hb (α) average DPR was carried
out with the assumption that ion intensities (I) of protein drug conjugate (PDC) species
observed in mass spectrum correlate to their real quantities. The percentage (%) of PDCs
with same DPR was calculated using this equation:
Percentage (%) = ∑ IPDCs with same DPR/∑ I total PDC (1)

Average DPR of Hb (α) was calculated to be 1.4 using the equation as follows [24]:
Average DPR= ∑ (percentage of PDCs with same DPR×number of loaded drugs) (2)

As anticipated, there are a few ion peaks representing Hb (α)/phosphonoacetate conjugates
(see Figure 3.3.).
ESI mass spectrum averaged from 38.7 min to 47 min of reverse phase chromatogram
(see Figure 3.2.) indicates that it contains Hb (α)/PMEA conjugates and Hb (β)/PMEA
conjugates (see Figure 3.4.). The most abundant ion peak (m/z 882.14 charge state 19+) in
a region (m/z 880-930) of this mass spectrum represents Hb (β) conjugated with two
PMEApa (mass addition 377.19×2 Da) and one phosphonoacetate (mass addition 122.02 Da)
(see Table 3.2.). The ion peak (m/z 883.82 charge state 19+) is assigned as the oxidized form
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of the previously mentioned Hb (β)/PMEA conjugate (m/z 882.14 charge state 19+) due to a
31.92 Da mass addition (accuracy: 4.7 ppm). The presence of this peak suggests the
oxidation of Cys residues into their sulfinic acid derivatives with a 32 Da mass addition [90,
91]. This modification originates from the commercial Hb which is already oxidized [91]. The
average DPR for Hb (β) was calculated to be 1.8 using the same method applied on Hb (α)PMEA conjugates. Therefore, the average DPR for intact Hb (α2β2) can be calculated to be
6.4 if conjugation does not interrupt formation of Hb tetramer.
3.3.3. Characterization of haptoglobin∙hemoglobin/adefovir conjugates complex using
native ESI-MS.
There are two equilibria: (α2β2)⇌2αβ and 2αβ⇌2α+2β in Hb’s solution at neural pH
[92], allowing the access of reaction intermediates (sulfo-NHS ester of PMEApa) to the
binding areas. The crystal structure of human Hb (pdb: 2DN2) indicates that the binding
interface of two αβ dimers in Hb includes two amino acid residues (i.e. αV1 and αK99)
which contain primary amines [93]. Those residues probably participate in the
conjugation due to the exposed interface. Based on the crystal structure of human Hp∙Hb
complex (pdb: 4X0L), Hb αV1 and αK99 display direct contact with corresponding residues
(A382, V383 for αV1 and A288, F290 for αK99) in Hp via hydrogen bonding and Van der
Waals interactions (see Figure 3.5.) [80]. Therefore, PMEApa’s incorporation at these two
sites (i.e. Hb αV1 and αK99) probably interrupt the binding between Hp and Hb, lowering
the actual drug loading on Hp·Hb complex. Native electrospray ionization mass
spectrometry (native ESI MS) provides an elegant way to evaluate this impact because it
preserves non-covalent interactions in gas phase. This approach can be used to determine
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the DPR at Hp∙Hb complex level. The Hp∙Hb/PMEA conjugates complex was prepared by
incubating Hp with Hb-PMEA conjugate (α*β*)2 at 1:4 molar ratio. The resultant protein
complex was fractionated by size exclusion chromatography (SEC) prior to analysis by
native ESI MS. The off-line ESI mass spectrum of the earlier eluting species (a fraction
collected within the 8.3-9.7 min elution window) (see Figure 3.6.) acquired under nearnative condition indicates that the ionic species confined to a narrow m/z window 5000 6000 corresponds to Hp∙Hb/PMEA conjugates complex [Hp∙(α*β*)2] (see red trace in
Figure 3.7.). Its mass is calculated as 161 kDa based on m/z values for the centroids of the
four most abundant peaks (m/z 5196±60, charge state 31+; m/z 5369±90, charge state
30+; m/z 5552±90, charge state 29+; m/z 5755±50, charge state 28+). This mass is 3.6
kDa higher than the theoretical mass for the Hp·Hb/PMEA conjugates complex (calculated
as 157,345.4 Da for the major glycoform of Hp and assuming 6.4 PMEApa payloads on the
sequences of all proteins involved), and a mismatch of this magnitude is to be expected
given the extensive solvation of large protein ions generated by native ESI [94, 95].
Meanwhile, the off-line ESI mass spectrum of SEC fractionated Hp·Hb complex was
acquired under the exact same condition used by Hp·Hb/PMEA conjugates complex (see
black trace in Figure 3.7.). The mass of Hp·Hb complex was calculated to be 159.7 kDa
using m/z value of centroids of most abundant peaks, 1.3 kDa lower than that of
Hp∙Hb/PMEA conjugates complex. That mass difference is equivalent to 3.4 average drug
to Hp·Hb complex ratio (mass addition of each PMEApa conjugation: 377.19 Da). This
mismatch of DPRs between protein complex and tetrameric Hb indicates that not all of
Hb/PMEA conjugates participate in binding with Hp. It is possible that conjugations occur
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in or near the association interface (e.g., Hb αV1 and αK99) between Hb and Hp and affect
their binding. Since the binding interface between Hb and Hp highly overlaps with that of
two αβ dimers, these conjugations probably impact the formation of Hb tetramers.
Therefore, the actual DPR for intact Hb can be adjusted to be 3.4. Since those equilibria
of Hb in aqueous solution are pH dependent [93], a slight increase of solution pH favors
the formation of Hb tetramer. Under this circumstance, the binding interface of two αβ
dimers is buried, inaccessible to those reaction intermediates. As a result, this association
region on Hb can be preserved for binding with Hp. Despite those binding interruption,
other lysine residues on Hb (α) and Hb (β) are located far away from Hb’s interaction
regions with Hp, therefore, drug conjugations at those sites probably exert no impact on
loading adefovir to Hp via Hb and Hp binding.
After successful loading of adefovir to Hp·Hb complex, it is necessary to evaluate
whether this targeted delivery system improves the pharmacokinetic profiles of the drug.
Quantitation of exogenous Hp·Hb complexes carrying adefovir compounds in biological
matrices can be performed by tagging these protein carriers with no-cognate metals (e.g.,
gallium) and measuring the latter’s concentration (will be converted to Hp·Hb complexes’
concentration based on tagging stoichiometry) via inductively coupled plasma mass
spectrometry (ICP-MS) [59]. However, since drug release might occur before reaching
therapeutic targets due to enzymatic catalyzed or chemically induced cleavages, the DPR
for Hp·Hb complex may vary during the transport, affecting the accuracy of conjugated
drug’s quantitation. To solve this problem, an attractive ruthenium (Ru) based metal tag
designed for conjugated PMEApa is currently being pursued in our laboratory. Dual metal
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labeling approach allows ICP-MS to measure concentrations of gallium and ruthenium in
biological samples simultaneously, which will be converted to concentrations of Hp∙Hb
complexes and their payloads respectively. This method can be used to monitor drug
release of Hb/adefovir conjugates before its arrival at target sites or after their
internalization [96].
3.4. Conclusion
The development of small molecule drugs is frequently impeded because of their
unsatisfactory pharmacokinetic profiles [97]. The off-target toxicity of those drugs is one
of main causes for their clinical failures [98]. For example, adefovir is a promising
antiretroviral drug designed for inhibition of HIV’s reverse transcription. However, its
prodrug (i.e. adefovir dipivoxil)’s clinical trials in anti-HIV therapy was terminated owing
to nephrotoxicity. This problem can be solved by targeting adefovir to HIV’s cellular
reservoirs (e.g., macrophage, monocyte) by protein based carriers to reduce drug’s
exposure to kidney. Conjugation of adefovir with a model carrier protein, lysozyme, was
carried out using a phosphate linker. Despite the success, this reaction requires long term
stirring and basic pH to assure a satisfactory drug loading, increasing a risk of protein
aggregation and post-translational modifications (e.g., deamidation). In order to solve this
problem, we developed a phosphonoacetate linker to enable efficient and robust
conjugation of adefovir with Hb, a real protein carrier. This reaction using the new linker
can be performed at physiological pH with less than one hour stirring, reducing the loss
and damage of Hb. The average DPRs for Hb α- and β-chain drug conjugates after 30 min
reaction were determined by mass spectrometry to be 1.4 and 1.8 respectively. Although
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linker (i.e. phosphonoacetate) derived byproducts were observed in the mass spectrum,
Hb-PMEA conjugates remain the major components of the protein mixtures. The actual
number of PMEA loading on Hp·Hb complex was determined to be 3.4 by native ESI based
measurements, lower than the assumed DPR 6.4 (based on DPRs for Hb α- and β-chains).
This result indicates that conjugation may take place in the binding interface between Hb
and Hp, impacting their association. This problem can be solved by burying the interfaces
between two αβ dimers during the reaction by a slightly increased pH which favors the
formation of Hb tetramer.

52

Elution time, min
0
15
20
25
30
35
40
45
50
55
Table 3.1. Elution gradient
chromatography.

Mobile phase A (0.1%
formic acid, 0.02% TFA in
water), %
63
63
60
60
57
57
54
54
51
51
for Hb/PMEA conjugates’
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Mobile phase B(0.1% formic
acid, 0.02% TFA in
acetonitrile), %
37
37
40
40
43
43
46
46
49
49
isolation by reverse phase

Hb
α
β
mass addition of (PA)(PMEA) conjugation
mass addition of (PA) conjugation

average mass, Da
15126.36
15867.22
377.19
122.02
measured mass,
Da
15125.4
15247.26
15369.3
15502.32
15624.36
15746.4
15879.42
16001.28
16256.4

α
α (PA)
α (PA)2
α (PA)(PMEA)
α (PA)2(PMEA)
α (PA)3(PMEA)
α (PA)2(PMEA)2
α (PA)3(PMEA)2
α (PA)3(PMEA)3

calculated mass,
Da
15126.36
15248.38
15370.4
15503.55
15625.57
15747.59
15880.74
16002.76
16257.93

β (PA)(PMEA)
16242.72
16244.41
β (PA)2(PMEA)
16364.7
16366.43
β (PA)3(PMEA)
16487.64
16488.45
β (PA)2(PMEA)2
16620.84
16621.6
β (PA)3(PMEA)2
16741.66
16743.62
β (PA)4(PMEA)2
16864.78
16865.64
β (PA)3(PMEA)3
16996.64
16998.79
β (PA)4(PMEA)3
17120.71
17120.81
Table 3.2. Measured masses and calculated masses for Hb/PMEA conjugates shown in
Figure 3.3. and 3.4. For Hb (α)/PMEA conjugates and Hb (β)/PMEA conjugates, the number
of PA equals that of PMEA in their notation. For phosphonoacetate derived impurities, the
number of PA differs from that of PMEA in their notation.

54

Figure 3.1. Zoomed view of ESI mass spectrum of adefovir phosphonoacetate
(PMEApa) acquired under negative ion mode.
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Figure 3.2. Reverse phase chromatogram (brown) of Hb/PMEA conjugates acquired at
wavelength 280 nm (from online reverse phase LC-MS analysis).
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Figure 3.3. Top: ESI mass spectrum averaged from 29.8 min-38.5 min of reverse phase
chromatogram (see Figure 3.2.) for separation of Hb/PMEA conjugates. Bottom: zoomed
view of above mass spectrum. For Hb (α)/PMEA conjugates, the number of PA equals
that of PMEA in their notation. For phosphonoacetate derived impurities, the number of
PA differs from that of PMEA in their notation.
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Figure 3.4. Top: ESI mass spectrum averaged from 38.7 min-47 min of reverse phase
chromatogram (see Figure 3.3.) for separation of Hb/PMEA conjugates. Bottom: zoomed
view of above mass spectrum. For Hb (β)/PMEA conjugates, the number of PA equals
that of PMEA in their notation. For phosphonoacetate derived impurities, the number of
PA differs from that of PMEA in their notation.
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Figure 3.5. Selected binding interface between human Hb (α) (yellow) and Hp (purple)
(extracted from pdb: 4X0L), αV1 involves in hydrogen bonding interaction with A382
(4.2Å) and V383 (2.8Å) in Hp (Top). αK99 engage the hydrogen bonding interaction
with A288 (3.5 Å) in Hp (Bottom).
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Figure 3.6. Size exclusion chromatogram of Hp/Hb/PMEA conjugates mixture acquired
at 280 nm.
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Figure 3.7. Off-line ESI mass spectra of SEC fractionated Hp ∙ Hb/PMEA conjugates
complex (red) and Hp∙Hb complex (black) (collected over 8.3-9.7 min, see Figure 3.6)
acquired at near native condition. The insert is the zoomed view of charge state 30+ and
29+ of Hp∙Hb/PMEA conjugates complex (red) and Hp∙Hb complex (black). The asterisk
label means PMEA conjugated protein.
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Scheme 3.1. Reaction scheme of Hb adefovir conjugation using phosphonoacetate linker.
Formation of transition zwitterion in PMEA-Im probably occurs due to the electrondonating effect from methylene group which is adjacent to phosphonoimidzolide moiety.
In this transition zwitterion, imidazole becomes a good leaving group which can be
replaced by nucleophiles easily.
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CHAPTER 4
EVALUATION OF GALLIUM AS A TRACER OF EXOGENOUS HEMOGLOBINHAPTOGLOBIN COMPLEXES FOR TARGETED DRUG DELIVERY APPLICATIONS
4.1. Introduction
Haptoglobin (Hp) is an acute phase plasma protein, whose raison d'être is
sequestration of free hemoglobin (Hb) in circulation to avoid possible renal damage and
other negative physiological consequences of intravascular hemolysis [18]. In the past,
interest in Hp was caused primarily by its obvious ability to attenuate efficiency of oxygen
transport by Hb-based blood substitutes [99], as well as its involvement in iron acquisition
by several pathogens [100]. More recently, better understanding of the Hp-mediated
pathway of Hb clearance [55, 101] has provided strong indications that this protein may
also be used for targeted drug delivery, taking advantage of the fact that Hb·Hp
complexes are processed (catabolized) in macrophages [17, 102]. Since macrophages and
their progenitors (monocytes) play a prominent role in establishing certain types of viral
infections (including human immunodeficiency virus, HIV), virus dissemination, and
development of viral reservoirs [103], the ability to deliver anti-viral therapeutics directly
to macrophages (e.g., by conjugating them to either Hp or Hb·Hp complexes) should
result in a dramatic improvement of the drug efficacy. Another high value target for such
a strategy might be the hepatitis C virus (HCV), since there is evidence that resident liver
macrophages are infected by and support replication of HCV [104]. In addition to viral
infections, a similar strategy can be envisioned as a way to design novel therapies against
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certain types of cancers (most notably acute myeloid leukemia), as the
monocyte/macrophage lineage specificity of CD163 (cell-surface receptor that recognizes
Hb·Hp complexes and assists their internalization [17, 56]) expression is preserved
beyond malignant transformation [105, 106]. The specificity of targeted cytotoxin
delivery in this case would be particularly beneficial, as Hp-mediated drug delivery
specifically to the CD163-expressing cells will be limited to monocytes and macrophages
and spare normal stem cells in the bone marrow [105].
As is the case with all drug delivery strategies utilizing transport proteins for targeted
delivery, successful design of therapies based on Hp as a delivery vehicle (e.g., Hpcytotoxin or Hp-antiviral conjugates) will critically depend on the ability to trace the
drug/protein conjugate within the organism following its administration to obtain
detailed and reliable pharmacokinetics and pharmacodynamics information [26, 107,
108]. While the protein quantitation strategies are now well-established, a unique
challenge for reliable and sensitive localization and quantitation of protein therapeutics
based on or mimicking abundant endogenous proteins (such as Hp) arises from the fact
that such measurements are carried out on the varying (and often unpredictable)
background of endogenous molecules whose structure is identical to that of the
exogenous (administered) proteins. This makes it highly problematic to use classic
techniques of protein quantitation, such as enzyme-linked immunosorbent assay (ELISA)
[109, 110], which remains one of the most popular and sensitive techniques in the field
[111, 112]. Recently, mass spectrometry (MS) emerged as a powerful tool for protein
quantitation in complex biological matrices, enabling highly sensitive and selective
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measurements both in the field of proteomics [113] and in a variety of pharmacokinetic
studies [30, 114, 115]. Most of these applications rely on stable isotope labeling of
proteins or their fragments as a means of quantitation [116]. However, because most
cost-effective labeling strategies introduce the isotopic label during the proteolytic step
[117], they frequently fail to make a distinction between an exogenous protein and its
endogenous counterpart if the degree of structural similarity between them is very high.
Such a distinction can be made if the isotopic label is introduced at the whole protein
level (e.g., during the expression of the exogenous protein), but this usually results in a
dramatic increase of the production costs.
An alternative approach to introducing distinct labels to exogenous proteins that can
be readily identified by MS takes advantage of the possibility to attach a metal tag to the
protein surface, making it detectable by inductively coupled plasma (ICP) MS [35]. A very
important advantage of this approach is the high sensitivity afforded by ICP MS
measurements and the possibility to select a non-cognate metal tag that would have
minimal spectral interferences. However, an obvious drawback of these strategies is their
reliance on chemical modification of the protein surface, which may alter its properties,
including interactions with physiological partners and therapeutic targets. Recently, we
introduced a solution to this problem that can be used when the exogenous protein is a
metalloprotein (e.g., ferro-protein transferrin used to deliver drugs either to malignant
cells or across physiological barriers [118]), where the cognate metal is replaced with a
non-cognate one without altering protein conformation or compromising the receptor
recognition. For example, replacing Fe3+ with In3+ in transferrin allows this protein to be
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detected with high sensitivity in blood and tissue homogenates of animals using ICP MS,
and its distribution maps to be obtained by imaging with laser ablation ICP MS [119].
In this work we extend this approach to Hp, which is not a metalloprotein. This is done
by substituting Fe3+-bound protoporphyrin IX (heme) with the protoporphyrin IX molecule
that contains a non-cognate metal (gallium) within Hp’s counterpart, Hb prior to forming
the Hp·Hb complex (which is the molecular entity recognized by the cell-surface receptor).
Despite relatively low stability of Ga-substituted Hb (HbGa), it binds readily to Hp, with the
resulting Hp·HbGa complex remaining remarkably stable under physiological conditions.
The non-cognate metal allows this complex to be readily detected in serum samples at
levels well below 10 nM, which makes it suitable for pharmacokinetic studies.
4.2. Experimental
Materials. Hp phenotype 1-1 was purchased from Athens Research & Technology
(Athens, GA), and human Hb was purchased from Sigma-Aldrich Chemical Company (St.
Louis, MO). Gallium (III)-protoporphyrin IX (Ga-PP) was purchased from Frontier Scientific
(Logan, UT). Gallium, plasma standard solution (10,000 mg/L) was purchased from Alfa
Aesar (Haverhill, MA). Nitric acid (69.2% aqueous solution) and hydrogen peroxide (31.4%
aqueous solution) were purchased from Fisher Scientific (Fair Lawn, NJ). Human serum
samples were provided by the Department of Kinesiology, University of MassachusettsAmherst (Amherst, MA). All other reagents and solvents used in this work were of
analytical grade or higher.
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Methods. The apo-form of human Hb was prepared using a modified acidic acetone
precipitation method described in detail elsewhere [120]. Briefly, cold (4 OC) aqueous
solution of 200 µM Hb in 150 mM ammonium acetate was infused into cold (0 OC) 2 M
HCl acetone solution (mixing ratio 1:50), followed by vigorous mixing for 5 min. The fluffy
colorless precipitate was collected by pipette, centrifuged at 4 OC and lyophilized. The
lyophilized apo-Hb was dissolved in 10 mM ammonium acetate solution to a final
concentration of 0.42 mg/mL and placed on ice for at least 1 hour, followed by the
addition of 1 mM Ga-PP methanol solution at a 37:1 ratio (v:v). The molar ratio of Ga-PP
to globin monomers was estimated to be 1:1. This solution was incubated on ice for 1
hour to produce HbGa, followed by ESI MS and/or UV/Vis absorption analyses at room
temperature. The Hp·HbGa complexes were produced by adding 44 µM solution of Hp in
150 mM ammonium acetate to the ice-cold HbGa solution at a mixing ratio of 1:13 (v:v),
corresponding to an 8:1 molar ratio of HbGa globins (monomers) to Hp.
A Nanodrop 2000c spectrophotometer (Thermo Scientific, Waltham, MA) was used
to measure the UV-Vis absorption spectra of HbGa and Hp∙HbGa and evaluate their stability
at 37 OC by monitoring the decay rates of their Soret bands within the time interval
ranging from 0.5 to 24 hrs. The measured intensities of the Soret bands were fitted to
exponential decay curves to estimate the half-life values. SEC fractionation of Hp∙HbGa
was carried out using Agilent 1100 (Agilent, Santa Clara, CA) liquid chromatograph
equipped with a TSKgel G3000SWxl (Tosoh, Tokyo, Japan) column. A 150 mM ammonium
acetate solution was used as mobile phase in the separation at a flow rate of 0.8 mL/min.
The absorbance was measured at 280 nm and 415 nm. SEC fractions were manually
67

collected and characterized by native electrospray ionization (ESI) MS with a QStar-XL
(AB/Sciex, Toronto, Canada) hybrid quadrupole/time-of-flight mass spectrometer
equipped with a nano-spray source.
Human serum spiked with Hp∙HbGa was prepared using the metal-labeled protein
solution, in which the total protein concentration was determined by UV absorption
measurements at 280 nm using the molar absorptivity (165,700 M-1·cm-1) calculated
based on the sequence of both Hp and Hb. The detection of Ga in the spiked serum
samples was carried out using NexION 300X (PerkinElmer, Waltham, MA) ICP mass
spectrometer following its overnight digestion with 49% HNO3 and 7% H2O2 (by volume)
at 37 OC. The kinetic energy discrimination (KED) mode was used to reduce polyatomic
interference. The ICP mass spectra were obtained for both the spiked serum sample and
the blank (Ga-free serum) by scanning the quadrupole in the m/z range of 50-150 u.
4.3. Results and discussion
4.3.1. Rationale for selecting gallium as a metal tracer.
Hp is not a metalloprotein, but its binding partner Hb is. Since their association is very
strong [121], and the Hp·Hb complex is in fact the molecular entity recognized by CD163
on the macrophage surface (an obligatory first step in its internalization), Hb appears to
be an excellent choice for introducing a metal tag that can be used to trace the entire
complex. Although the cognate metal (iron) is obviously unfit to be a good tracer (due to
its abundance in living organisms), substitution of this metal with a non-cognate one will
produce a good tag as long as it does not disrupt (i) the heme interaction with each of the
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globin chains (both α and β), and (ii) the association of Hp with the reconstituted Hb.
There is a wide variety of non-ferrous metals that can be complexed with protoporphyrin,
some of them having physiological significance [122]. However, gallium appears the best
substitute for the cognate metal due to the filled d-shell, very close size match (0.62 Å vs.
0.65 Å for Fe3+) and its trivalency (even though heme-bound iron exists in the ferrous state
inside erythrocytes, hemolysis results in its rapid oxidation to Fe3+, leading to formation
of met-hemoglobin, which is the form interacting with Hp in circulation). In fact, Gasubstituted protoporphyrin (Ga-PP) is commonly considered a good model to study the
heme-globin interaction [123]. Furthermore, gallium is not an essential metal and, unlike
most of its neighbors in the periodic table, it is not present in the human body at levels
exceeding 0.2 ppb [124] (unless the subjects had chronic exposure to this metal [125]),
which should minimize interferences in ICP MS and LA-ICP MS measurements.
4.3.2. Production of HbGa and evaluation of its stability.
A recent study by Pinter et al. demonstrated that Ga-PP can be readily incorporated
in myoglobin, a protein that is highly homologous to the Hb α- and β-chains, although the
Ga-PP reconstituted protein remained stable only at low temperatures [123].
Incorporation of Ga-PP into Hb in our work was also carried out at low temperature. The
correct placement of the prosthetic group within the polypeptide chains was indirectly
verified by UV-Vis absorption spectroscopy (Figure 4.1.), which shows a significant red
shift of the B-band of Ga-PP (from 406 nm to 415 nm), consistent with the formation of
the Soret band; a very similar Ga-PP “insertion signature” was previously reported for
myoglobin [123]. A more detailed examination of the composition of the products of Hb
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reconstitution with Ga-PP was carried out using native ESI MS, which revealed (αGaβGa)2
as a species giving rise to the most abundant ionic signal (Figure 4.2.). The general
appearance of this mass spectrum is very close to that previously reported for commercial
ferro-Hb, HbFe [126, 127]. In addition to the tetrameric species, both dimers and
monomers are observed, alongside some heme-deficient species (labeled with open
circles in Figure 4.2.). Some of these Ga-PP deficient species (i.e., ions lacking a prosthetic
group) may be produced by gas phase dissociation, as we note the presence of ions in the
low m/z region of the mass spectrum whose masses and isotopic distribution allow them
to be unequivocally identified as singly charged Ga-PP (see the inset in Figure 4.2). These
ions are likely to be produced in the gas phase (heme loss is a very common fragmentation
pathway for all globins), but it cannot be ruled out that at least some heme-deficient
species are present in solution as well. Indeed, the presence of heme-defecient
assemblies was previously observed even for HbFe [126], and was ascribed to the presence
of oxidized β-chains in the commercial Hb samples which have diminished ability to retain
the heme group [127] and significantly enhanced flexibility [128].
Unlike HbFe, HbGa was observed to precipitate even at 4 OC, which manifested itself by
clouding of the protein solution, followed by formation of visible solid precipitates. One
possible explanation for this increased aggregation propensity is that the negatively
charged Ga-PP in solution may electrostatically repel the negative β-globin in which Cys93
(pKa = 8.2) is oxidized to cysteine sulfinic acid (pKa = 2) or sulfonic acid (pKa = -3) [129].
This would exclude partial solvent for β-globins and expose hydrophobic residues,
triggering nucleation and irreversible aggregation [130]. The rate of HbGa loss in solution
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at physiologically relevant temperature (37 OC) was measured by monitoring the intensity
Soret band using SEC-purified HbGa as a starting material (Figure 4.3.). A very dramatic
decrease of the band intensity is observed within few hours (compare the red and pink
traces in Figure 4.3. corresponding to measurements taken 2 hours apart). The rate of the
Soret band decay in HbGa sample is consistent with the half-life of this protein being only
2 hours, indicating its high vulnerability under conditions similar to those encountered in
circulation.
Hp is known to exert a significant stabilizing effect on proteins it binds, and for that
reason is frequently referred to as an “extracellular chaperon” [131, 132]. Since the
therapeutic action of Hp/drug (or Hb/drug) conjugate could be exerted only within the
context of Hp·Hb complex, possible stabilization of HbGa by Hp would be very relevant visà-vis ensuring the reliability of the measurements by minimizing or indeed eliminating the
loss of the protein due to aggregation. In order to evaluate the stability of HbGa in complex
with Hp, a mixture of the two proteins was incubated at 4 OC followed by SEC fractionation
(Figure 4.4.). Both SEC fractions exhibited absorbance at 415 nm, and were assigned as
Hp·HbGa (elution window 8.9-9.8 min) and free HbGa (elution window 12.5-14 min); this
assignment was confirmed by native ESI MS analysis of both fractions (vide infra).
Monitoring the intensity of the Soret band for the early-eluting species (assigned as
Hp·HbGa complex) over a one-day period following the fraction collection revealed a
markedly increased stability compared to free HbGa. In fact, the measured rate of the
Soret band decay was consistent with the half-life of ca. 24 hours. This time window
appears to be more than adequate for the measurements of biodistribution of Hp-based
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drugs targeting macrophages, as the physiological clearance of Hp·Hb occurs on a
significantly shorter time scale [133].
4.3.3. Characterization of Hp∙HbGa.
The SEC fractions of the HbGa/Hp mixture (1.4 mg/mL and 0.27 mg/mL, respectively)
incubated at 4 OC overnight were also analyzed by native ESI MS. The off-line ESI mass
spectrum of the earlier eluting species (a fraction collected within the 8.9 – 9.8 min elution
window) acquired under near-native condition (blue trace in Figure 4.4., bottom) contains
contributions from several ionic species. The ionic signal of the major contributing species
is confined to a narrow m/z window 5000 – 6000, and its mass is calculated as 157.7 kDa
based on m/z values for the centroids of the three most abundant peaks. This mass is 2.7
kDa higher than the theoretical mass for the Hp·(αGaβGa)2 complex (calculated as
154,984.6 Da for the major glycoform of Hp and assuming no modification to the
sequences of all proteins involved), and a mismatch of this magnitude is to be expected
given the extensive solvation of large protein ions generated by native ESI [94, 95]. Indeed,
increasing collisional activation of ions in the ESI interface region by stepping up the declustering potential resulted in a noticeable shift of these peaks towards lower m/z values
(consistent with the notion of the partial loss of small molecules from the solvation shell
of the surviving complex ion), although this also increased the efficiency of other
dissociation channels.
A cluster of low-abundance peaks at high m/z (> 6,000 u) corresponds to the products
of gas-phase dissociation of Hp·(αGaβGa)2 ions proceeding via a loss of a single globin chain
(the complementary fragments populate the low m/z region of the mass spectrum (<
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2,000 u). This dissociation channel (asymmetric charge partitioning, where a single highly
charged polypeptide chain is ejected from the complex ion), is usually a preferred
dissociation channel of protein complexes in the gas phase [134, 135]. Lastly, a group of
lower-abundance ions populate a narrow m/z region of the mass spectrum (4,500-5,000
u) and partially overlaps with the ionic signal of Hp·(αGaβGa)2. The masses of these species
are consistent with unsaturated Hp/Hb complex (i.e., Hp·αGaβGa). Since the extent of
multiple charging of these species is nearly the same as that of Hp·(αGaβGa)2, it seems
highly unlikely that these ions represent products of gas phase dissociation. Even though
in some cases asymmetric charge partitioning is not the only channel of gas phase
dissociation of protein assemblies [136], transition from Hp·(αGaβGa)2 (charge states +27
through +30) to Hp·αGaβGa (charge states +27 and +28) in the gas phase would require
removal of hemoglobin dimer αGaβGa carrying very few charges from the multiply charged
assembly, a process that appears to be thermodynamically unfavorable [135]. Although
the solution-phase origin of the observed Hp·αGaβGa species might seem to contradict the
observation that the ionic signal intensity ratio Hp·(αGaβGa)2/Hp·αGaβGa decreases at
higher collisional activation, this is likely to be a consequence of Hp·(αGaβGa)2 ions being
more prone to gas phase dissociation (and suffering greater population loss when the
collisional energy is increased).
While it might seem puzzling that the Hp/HbGa complexes of different stoichiometries
co-elute in SEC, one must remember that Hp has an extended, dumbbell-shaped
conformation, and binding of hemoglobin does not result in a noticeable increase of its
hydrodynamic radius [78]. A very modest increase of the extent of multiple charging in
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native ESI MS upon Hp association with either αFeβFe (as reported in [94]) or αGaβGa (as
seen in Figure 4.4.) is also consistent with a relatively insignificant increase of the physical
size of the macromolecule [137]. Therefore, it should not be surprising that Hp·(αGaβGa)2
and Hp·αGaβGa cannot be separated by SEC. The practical ramifications of this (as related
to the ultimate goal of our work) are quite significant, as the presence of the partially
unsaturated Hp/Hb complex in the Ga-labeled sample means that the Ga/Hp molar ratio
is less than the presumed ratio of 4:1. The magnitude of the correction can be estimated
from the ionic signal intensity ratio Hp·(αGaβGa)2/Hp·αGaβGa in the native ESI mass
spectrum acquired under mild conditions in the ESI interface region (such as that shown
in Figure 4.4.). Even though the relative ion current intensity of a particular species cannot
be simply equated to its fractional concentration in solution [138], the correlation could
be reasonably close, especially at lower protein concentrations [139]. Based on these
considerations, we evaluate the Hp·(αGaβGa)2/Hp·αGaβGa concentration ratio in solution as
3.3 :1, which corresponds to the Ga/Hp labeling ratio of 3.5 :1.
4.3.4. ICP-MS detection of Hp∙HbGa in human serum.
Knowing the Ga/Hp labeling ratio provides an opportunity to determine the
concentration of this protein (or protein/drug conjugates) in complex biological matrices
by measuring the levels of Ga. Ga can be readily detected in a variety of biological matrices
using ICP MS, although both of its stable isotopes are known to have spectral
interferences, such as

138Ba2+

for

69Ga+,

and

40Ar31P+

and

35Cl36Ar+

for

71Ga+

[140, 141].

Figure 4.5. shows a relevant region of the ICP mass spectrum of a blank (human serum
that had not been doped with Ga in any form), where low-abundance ionic signal is
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observed at both m/z 69 and 71, even though the measurements were carried out in the
kinetic energy discrimination (KED) mode to reduce polyatomic interferences. Spiking the
serum sample with Hp/HbGa (final concentration of Hp in the sample 8.4 nM) resulted in
a noticeable increase of the ionic signal at both m/z values (see the red-filled curve in
Figure 4.5.). The magnitude of the signal intensity increase exceeds an order of magnitude,
suggesting that Ga can be successfully used as a tracer in pharmacokinetic studies of Hpbased therapeutics (the protein therapeutics serum concentration range that needs to be
accessible to measurements is estimated to span from sub-µM to low-nM levels [142]).
Carrying out the measurements of Ga concentration in a common “hopping mode”
(where only the ionic currents of isotopes of interest are measured, such as 69Ga, 71Ga,
and the internal standards), as opposed to the continuous quadrupole-scanning mode
(shown in Figure 4.5.) will result in further increase of the measurement sensitivity. This
will allow exogenous Hp to be detected not only in circulation at concentrations that are
significantly below typical levels of the endogenous protein in human plasma [143], but
also in various tissues despite unfavorable tissue/serum ratios.
The goal of the present work was to develop a method of detecting and measuring
exogenous Hp in complex biological matrices (such as blood plasma), with the subsequent
aim of extending this approach to include Hp-based antiviral therapies. One particularly
attractive target currently pursued in our laboratory is Hp conjugated to analogs of
adefovir [46]. The latter is a small-molecule medicine that was initially designed as an HIV
treatment, but the clinical studies showed that absent targeted delivery to macrophages,
therapeutically active doses of adefovir are unsafe for patients. As a result, its clinical
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applications are now limited to the low-dose format to treat a lower value target,
hepatitis B virus [144]. Conjugation of adefovir to the Hp/Hb complex appears to be a
reasonable strategy to achieve the desired therapeutic outcome with a lower drug dosage
by virtue of targeted delivery. Quantitation of adefovir/Hp/Hb conjugates in biological
matrices could be also carried out with high specificity and sensitivity using Ga as a tag by
introducing a slight modification to the procedure described in the present work. In this
case, Ga/adefovir ratio can be determined by measuring the Ga/P ratio in the conjugate
sample by ICP MS (despite interferences from 14N16O1H+ and 15N16O+ [145], ICP MS allows
phosphorus to be monitored with a detection limit in the sub-ppb range [146]). Lastly, the
sensitivity of detection and quantitation of exogenous Hp or Hp/drug conjugates based
on metal tags may be further improved by exploring the utility of other metals beyond
gallium, since protoporphyrin IX can be substituted with a variety of non-ferric metals
[147].
4.4. Conclusions
Biopharmaceuticals remain one of the fastest growing sectors in modern medicine,
but their continued success hinges upon the ability to provide detailed and reliable
characterization of these complex therapeutic agents and their behavior in vivo.
Collecting pharmacokinetics data is a particularly challenging task for several protein drug
candidates, especially those that are structurally very similar or indeed identical to
endogenous proteins, e.g. those that enable access to specific target sites. Hp is one of
such proteins, as it can uniquely access macrophages, a trait that can be taken advantage
of for the purpose of targeted drug delivery in a variety of antiviral strategies. Tracing
76

exogenous Hp or Hp/Hb complexes in organisms can be very challenging, since these
measurements have to be carried out on the background of abundant (an varying)
endogenous Hp. We address this problem by substituting iron-bound heme group with
the gallium-bound protoporphyrin IX in Hb prior to complexing it with Hp. While Galabeled free Hb appears to be only marginally stable, the Hp/HbGa complex displays
remarkable stability on a time scale relevant for pharmacokinetic measurements. Gallium
is a non-essential metal and is not present in humans (absent any environmental or
workplace exposure to Ga-containing materials), which makes it a convenient tag that is
suitable for detection and quantitation of exogenous Hp/HbGa complexes in biological
matrices using ICP MS as a method of detection. Despite several spectral interferences,
Ga can be detected with sensitivity that is more than adequate for pharmacokinetic
studies of Hp-based therapeutics.
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Figure 4.1. UV-Vis spectra of a water/methanol solution of Ga-PP (purple), and
aqueous solutions of HbGa (red) and HbFe (brown)
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Figure 4.2. Native ESI mass spectrum of a 5 μM solution of HbGa (human Hb
reconstituted with Ga-PP) in 150 mM ammonium acetate acquired 60 min. after the
incubation. Open circles indicate hemoglobin species lacking one Ga-PP group (i.e.,
tetramers with three Ga-PP groups and dimers with a single Ga-PP group). The inset
shows a low m/z range of the mass spectrum containing the ionic signal of Ga-PP.
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Figure 4.3. UV-Vis absorption spectra of HbGa (red and pink) and Hp·HbGa (blue and
teal); the delay before the acquisition of the second spectrum in each pair was two
hours. The insert shows the evolution of the intensity of the Soret band in each sample
over a 24 hour time period.
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Figure 4.4. Top: Size exclusion chromatogram of Hp and HbGa mixture acquired at two
different wavelengths (280 nm, purple, and 415 nm, brown). Bottom: off-line ESI mass
spectra of SEC fractions acquired over 9-10 min (blue) and 13-14 min (red) time
windows. The shaded areas in the mass spectrum of the early-eluting fraction contain
gas phase fragment ions produced via asymmetric charge partitioning. Open circles
indicate hemoglobin dimers with a single Ga-PP group.
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Figure 4.5. Zoomed views of full-scan ICP mass spectra of human serum before (blue
trace) and after (red trace) addition of exogenous Hp·HbGa complex (the final
concentration of the protein in the sample is 8.4 nM).
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CHAPTER 5
DISSERTATION SUMMARY AND FUTURE DIRECTION
5.1. Dissertation summary
Proteins have emerged as promising carriers for small molecule drugs to improve
their pharmacokinetic profiles in recent years [148-150]. This protein mediated delivery
strategy heavily relies on the development of conjugation chemistry which are robust to
both protein and small molecule compounds. Traditional synthetic strategies designed for
a nucleotide reverse transcriptase inhibitor’s prodrug (adefovir dipivoxil which causes
sever nephrotoxicity in anti-HIV treatment) select aprotic solvents (e.g., DMF) as reaction
media, allowing the use of highly reactive chlorinating agents which is water-sensitive and
high temperature which probably damages proteins. In this dissertation, we developed a
novel and robust synthetic strategy to enable adefovir’s conjugation with protein to be
performed in aqueous solution. Adefovir compounds were phosphorylated prior to
reaction with carriers to avoid direct activation of their phosphonate groups by
carbonyldiimidazole, which produces hydrolytically unstable intermediate, adefovir
phosphonoimidazolide. The activated form of adefovir monophosphate (i.e. adefovir
monophosphorimidazolide) was much more stable than its non-phosphorylated
counterpart and was highly reactive towards primary amines and, to less extent, hydroxyl
groups on the lysozyme surface. Lysozyme/adefovir conjugates were successfully
produced using this novel synthetic strategy and were characterized by mass
spectrometry based analysis. This is the first time that protein based prodrug of acyclic
nucleoside phosphonate has been prepared in aqueous solution.
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The synthetic strategy was further optimized by introducing phosphonoacetate as a
linker to provide more robust reaction environment for protein carriers. This novel linker
was applied to the conjugation of adefovir with hemoglobin, a potential protein carrier
which targets CD163 receptors on macrophages with the assistance of haptoglobin.
Phosphonoacetate provides not only phosphonate group which acts as a strong
nucleophile to attack adefovir phosphonoimidazolide, but carboxylate group, a traditional
functional group which can be easily activated by EDC/sulfo-NHS. The use of this linker
facilitates the activated form of adefovir’s derivative (i.e. sulfo-NHS ester of adefovir
phosphonoacetate) to be attacked by primary amines from hemoglobin surface, allowing
the conjugation to be performed at neutral pH and with shorter stirring time, and
significantly reducing the risk of protein’s deamidation and aggregation. The application
of this phosphonoacetate linker can be extended to the entire groups of acyclic
nucleoside phosphonates (e.g., tenofovir and cidofovir) [40, 151] and cyclic nucleoside
phosphonates.
At last, a new ICP-MS based method was developed to detect and quantitate
exogenous Hb·Hp complex, a promising carrier for adefovir, by substituting iron-bound
heme group with the gallium(Ga)-bound protoporphyrin IX in Hb prior to complexing it
with Hp. While Ga-labeled free Hb appears to be only marginally stable, the Hp/HbGa
complex displays remarkable stability on a time scale relevant for pharmacokinetic
measurements. Gallium is a non-essential metal and is not present in humans (absent any
environmental or workplace exposure to Ga-containing materials), which makes it a
convenient tag that is suitable for detection and quantitation of exogenous Hp/HbGa
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complexes in biological matrices using ICP MS as a method of detection. Despite several
spectral interferences, Ga can be detected with sensitivity that is more than adequate for
pharmacokinetic studies of Hp-based therapeutics.
5.2. Future direction
The future directions of this dissertation include: (1) evaluation of the chemical
stability of protein/adefovir conjugates; and (2) investigation of pharmacokinetic(PK)
/pharmacodynamics(PD) profiles of protein conjugated adefovir payloads.
Chemical stability of the linkage between protein and its payload during the transport
and after arrival at therapeutic targets is an important property of the protein/drug
conjugates, which needs to be evaluated with regards to the safety and efficacy. Drug
cleavages which occur in the serum expose healthy tissues to those toxic compounds,
thereby raising safety concerns. On the other hand, ineffective drug release in lysosomal
environment probably leads to delayed efficacy. In order to assess the Lz/PMEA
conjugates (phosphate linker)’ drug release during and after the delivery, the hydrolytic
stability assay of those conjugates will be performed in mouse serum and lysosomal
extract respectively [152]. Cleaved PMEA or PMEAp compounds in biological matrices will
be enriched using solid phase extraction method (anion exchange resin) prior to
quantitation by LC/MS/MS approach. The phosphate linkage in Lz/PMEA conjugates is
predicted to have high stability in mouse serum due to the low abundance of acid
phosphatase and physiological pH which is unfavorable to catalytic activities of this
enzyme. Its dimerized form, a pyrophosphate linker used in antibody drug conjugates, has
been demonstrated to be stable after seven-day incubation with human serum [152],
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providing an adequate time window for protein mediated drug delivery. If Lz/PMEA
conjugates undergoes unexpected drug release in serum, the phosphate linker can be
replaced by phosphonoacetate and the resultant phosphonoester bond displays slow
cleavage when adefovir phosphonoacetate compounds are incubated with low
concentration of acid phosphatase in pH 5 (see Figure Appendix B). Lz/PMEA conjugates
are expected to release their payloads in lysosomal extract due to the the precense of
highly abundant acid phosphatase and the acidic environment which favors the catalytic
activities of this enzyme. If cleavages of PMEA in lysosomal extract are not effective, it is
feasible to introduce an additional phosphate between drug payloads (adefovir
monphosphate) and protein carrier to provide more space for acid phosphatase’s binding
and to facilitate the drug release [152]. Therefore, the optimized protein/PMEA
conjugates should maintain high stability in serum or other extracellular environment, but
be vulnerable to cleavages in the lysosome.
In addition to chemical stability of the linkage between adefovir and its protein carrier,
pharmacokinetic(PK)/pharmacodynamics(PD) profiles of the protein conjugated adefovir
are also very important. The concentration of these linked drug payloads can be
calculated using their protein carriers’ concentration in basis of fixed drug to protein ratio
(DPR). Therefore, in this dissertation, we developed a novel strategy to quantitate
adefovir’s protein carriers, Hb·Hp complex, by using gallium as a tracer and ICP-MS as an
analytical technique. However, quantification of protein carriers alone is not sufficient for
investigation of PK/PD properties of the conjugated drugs because the linkages between
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the payloads and carriers may undergo cleavages in extracellular environment, resulting
in varying DPRs which pose challenges to calculation of payloads’ concentration.
To address this problem, a p-cymene ruthenium (Ru) tag designed for protein
conjugated adefovir phosphonoacetate is currently being developed in our lab. The
preliminary MS data (see Figure 6.1) indicates a successful chelation of adefovir
phosphonoacetate with p-cymene ruthenium and a 1:1 adefovir to Ru ratio. The use of
dual metal labeling in quantitation of Hb·Hp complex/adefovir conjugates will provide us
absolute concentrations of Ga and Ru, as well as Ru/Ga ratio, allowing us to track both
protein carriers and linked drugs in biological matrices. Since both Ru and Ga are noncovalent tags, unexpected release of those metals during the delivery may take place,
thereby impacting the accuracy of this method. To evaluate the influence of metal loss on
the quantitation of drugs and proteins, dual-radiolabeled Hb·Hp complex/adefovir
conjugates will be prepared by conjugating adefovir (adenine-8-14C) phosphonoacetate
with 3H labeled hemoglobin (βCys93 residues are conjugated with N-ethyl-1,2-3Hmaleimide) and used to validate the metal labeling method [153]. Those radiolabels are
covalently attached to the linked drugs and proteins, overcoming the adverse impacts of
label loss on method’s accuracy. Dual channel liquid scintillation counter will be used to
record radioactivities of the biological samples, and to convert the rediosignals to
concentrations of adefovir and protein carriers. If the concentrations of linked drugs and
their protein carriers, which are measured by metal labeling approach (ICP-MS), are lower
than those determined by radiolabeling method, p-cymene Ru and gallium
protoporphyrin IX may undergo dissociation. To solve these problems, ligands (e.g., PTA,
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1,3,5-triaza-7-phosphaadamantane) can be selected to adjust the linked drugs’
coordination to ruthenium [154], improving the stability of Ru/adefovir complex. Some
metal (e.g., indium) protoporphyrin IX compounds or their derivatives can be evaluated
their ability to bind with hemoglobin. If the concentrations of conjugated adefovir and
protein carriers determined by both approaches are consistent, metal labels are stably
attached the conjugates and this dual metal labeling method is accurate and reliable.
In addition to the accuracy and reliability of this ICP-MS based quantitation method,
the selectivity of metal labeled protein conjugates during the delivery also needs to be
assessed because some labels (including ligands) may alter the protein surface property.
For example, the attachment of p-cymene ruthenium compounds to linked drugs might
increase the lipophilicity of the entire protein/adefovir conjugates, facilitating conjugate’s
cellular entry via lipid uptake pathway instead of CD163 receptor mediated internalization.
This impact of p-cymene ruthenium tag on selectivity of protein conjugates in delivery
can be evaluated by comparing the labeled conjugates’ cellular uptake in CD163+ and
CD163- cells. If both Ru and Ga are detected by ICP-MS in the lysates of CD163- cells, the
incorporation of p-cymene ruthenium with protein conjugates allows lipid uptake
pathway to compete with CD163 mediated internalization during cellular uptake process.
Under this circumstance, p-cymene can be replaced by other ligands with lower
lipophilicity such as imidazole.
If this dual metal labeling approach is accurate and does not affect the selectivity of
conjugates’ delivery, it can be used to evaluate the cellular uptake of Hb·Hp complex
conjugated adefovir in macrophages. These CD163 positive cells exposed to dual metal
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labeled protein/drug conjugates for varying time points will be lysed, the Ru and Ga
concentrations in the lysates will be measured by ICP-MS and used to quantitate
internalized linked adefovir compounds and their protein carriers respectively. Time
course of intracellular concentration of conjugated drugs which gain the entry by CD163
mediated internalization will be established and compared with that of free adefovir
compounds which enters cells via organic anion transporters. A higher intracellular
concentration of those linked drugs will demonstrate the ability of CD163 receptors to
elevate the cellular uptake of Hb·Hp complex conjugated adefovir. A lower intracellular
concentration of protein linked adefovir indicates a possible saturation of CD163
receptors by Hb·Hp complex. To address this problem, DPR of the protein/drug
conjugates can be elevated by elongating reaction time or using more effective synthetic
strategy. Another explanation for a lower intracellular concentration of conjugated drugs
is an interruption of CD163’s recognition on Hb·Hp complex by random conjugation. To
solve this problem, site specific conjugation of adefovir with protein carriers can be
performed by engineering cysteines (usually serine residues are replaced by cysteine
residues) into regions which are irrelevant to any protein associations and modifying
adefovir with maleimide to target those cysteine residues on protein surface.
Beyond investigation of PK properties, the use of ruthenium tag for protein
conjugated adefovir’s quantitation can be also extended to profiling drugs’
pharmacodynamics. The intracellular Ru concentration of HIV-infected macrophages
after internalization of metal labeled Hb·Hp complex/adefovir conjugates can be
correlated with drugs’ suppressive activities of HIV’s reverse transcription, generating an
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exponential curve which determines the half maximum inhibitory concentration (IC50) of
protein linked adefovir. If the IC50 of the conjugated drugs is higher than that of their free
counterparts which enter cells via organic anion transporters, the cleavages of
phosphonoester bonds in protein conjugated adefovir phosphonoacetate maybe delayed
or not completely. Under this circumstance, an extra phosphate can be introduced
between adefovir and phosphonoacetate, producing a compound which is called adefovir
monophosphate phosphonoacetate. This additional phosphate group provides more
space for lysosomal acid phosphatase’s binding and facilitates drug release, probably
decreasing IC50 of protein conjugated adefovir.
In summary, chemical stability of protein/adefovir conjugates in various biological
matrices (including serum and lysosomal extracts) will be evaluated in the future to
support optimization of conjugation chemistry. In addition, an accurate, reliable and
robust quantitation method using metal as labels and ICP-MS as analytical technique will
be developed in the future to investigate PK/PD profiles of conjugated adefovir
compounds.
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Figure 5.1. MS/MS analysis of ruthenium labeled adefovir phosphonoacetate (m/z 630
shown in the insert). The ion peak (m/z 586) corresponds to the resultant complex
which loses carboxylate group (Δm= 44 Da). The ion peak (m/z 508) represents that
complex which undergoes cleavage at phosphonoester bond close to
phosphonoacetate moiety (Δm= 122 Da). The ion peak (m/z 375) corresponds to the
complex which undergoes cleavage at phosphonoester bond close to adefovir moiety
(Δm= 255 Da).
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APPENDIX A
HYDROLYTIC TEST OF ADEFOVIR PHOSPHONOIMIDAZOLIDE
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Method: hydrolytic tests of adefovir phosphonoimidazolide (PMEA-Im) (diluted 1/100
from original DMF solution, final PMEA-Im’s concentration: 122 mM) were performed in
150 mM Tris-HCl buffer at pH 7.5. Hydrochloric acid was added to decrease the solution
pH from 7.5 to 5.5 after 1 hour of incubation. Chromatographic analysis of different
hydrolytic samples was carried out with Agilent 1100 (Agilent, Santa Clara, CA) liquid
chromatograph equipped with a 2 mm × 250 mm ProPac® SAX-10 (Dionex, Sunnyvale, CA)
strong anion-exchange column. Ammonium acetate at pH 7.0 was used for gradient
elution (50 mM in mobile phase A and 750 mM mobile phase B). The flow rate was
maintained at 0.2 mL/min. The linear gradient was run from 0% to 100 % mobile phase B
during a 20 min time period. UV absorbance at 260 nm was used for detection.
Results and discussions: adefovir (PMEA) sample (black trace) (see Figure Appendix A)
was run as a control to determine the elution sequence of those analytes which carry
different charges at pH 7. The peaks which elute before and after PMEA represent PMEAIm and dimeric form of PMEA respectively. Since both PMEA and its dimeric form carry
two negative charges at pH 7, their peaks highly overlap, but are distinguishable.
Chromatograms (light blue and blue traces) (see Figure Appendix A) of diluted PMEA-Im’s
hydrolytic samples (PMEA-Im’s concentration 1.2 mM) indicate a slow hydrolysis at pH
7.5. The addition of hydrochloric acid (red trace) accelerates PMEA-Im hydrolysis (see
Figure Appendix A). The extremely high abundance of PMEA and its dimeric form in ether
precipitated PMEA-Im sample (see purple trace in Figure Appendix A)suggests severe
hydrolysis and dimerization. This can be explained by that those PMEA-Im compounds are
highly condensed during the precipitation process (the volume was decreased from 300
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μl (DMF solution) to 30-40 μl (solid)). If there is a trigger such as acid or water molecules,
the rate of PMEA-Im’s hydrolysis and dimerization during precipitation process will be
significantly higher than in diluted solution. The hydrolysis and dimerization of PMEA-Im
during the ether precipitation, to some extent, can be defined as quenching of reaction
intermediates.
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Figure Appendix A. Chromatograms of hydrolytic samples of PMEA-Im.
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APPENDIX B
HYDROLYTIC TEST OF ADEFOVIR PHOSPHONOACETATE
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Method: hydrolytic test of adefovir phosphonoacetate (PMEApa) was performed in
150 mM NH4Ac buffer (pH 5) at 37oC . Acid phosphatase from sweet potatoes was added
to the solution at a final concentration 1.5 mg/ml, equivalent to 0.45-4.5 unit/ml.
Incubated samples were filtrated those enzymes by using 10 kDa cutoff prior to injection
into LC. Chromatographic analysis of hydrolytic samples at different time points (0, 24, 48
and 72 hours) was carried out with Agilent 1100 (Agilent, Santa Clara, CA) liquid
chromatograph equipped with a 2 mm × 250 mm ProPac® SAX-10 (Dionex, Sunnyvale, CA)
strong anion-exchange column. Ammonium acetate at pH 7.0 was used for gradient
elution (50 mM in mobile phase A and 750 mM mobile phase B). The flow rate was
maintained at 0.2 mL/min. The linear gradient was run from 0% to 100 % mobile phase B
during a 20 min time period. UV absorbance at 260 nm was used for detection.
Results and discussions: the starting material for this acid phosphatase mediated
hydrolytic test consists of adefovir (7.2 min), dimeric form of adefovir (7.9 min) and
adefovir phosphonoacetate (18.3 min). The black, red, blue and brown traces correspond
to hydrolytic samples after 0, 24, 48 and 72 hours incubation (see Figure Appendix B). The
half-life for the decay of PMEApa (cleavage of phosphonoester bond) can be estimated to
be 72 hours based on the integration of the peaks which elute at 18.3 min. This result
indicates that the phosphonoester linkage (or bond) in adefovir phosphonoacetate
compounds are cleavable when incubated with low concentration of acid phosphatase.
The half-life of this hydrolysis provides an adequate time window for successful delivery
of adefovir phosphonoacetate liked hemoglobin to its target site,
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Figure Appendix B. Chromatograms of hydrolytic samples of adefovir
phosphonoacetate.
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APPENDIX C
TOP-DOWN ANALYSIS OF HEMOGLOBIN ADEFOVIR CONJUGATE

99

Method: Hb/PMEA conjugates were purified using a Waters BioSuiteTM C18 column
(100Å, 3 µm, 2.1×50 mm) at a flow rate of 0.25 mL/min with the elution shown in Table
3.1.. Protein conjugates fractions were collected, mixed and analyzed by top down
analysis performed on a Bruker SolariX 7.0T Fourier transform ion cyclotron resonance
mass spectrometer (Bruker Daltonics, Billerica, MA). Collisionally activated dissociation
(CAD) of the mass-selected Hb (α)/(PA)2(PMEA)2 conjugate was carried out using the
parameters as follows: isolation window 993±5 Da; collision energy: 15 eV.
Results and discussion: CAD of Hb (α)/(PA)2(PMEA)2 ion at +16 charge state (m/z 993.5)
gives rise to a large number of fragment ions. Singly charged fragment ions are observed
in the low-m/z region of the mass spectrum (m/z 256 and 274) and their complementary
fragments are located at high m/z region [m/z 977.5 (+16), 1042.6 (+15) and 1041.4(+15)]
(see Figure Appendix C1). The most abundant of the two low-mass fragments (m/z 274)
corresponds to a (PMEA+H)+, produced by the cleavage of phosphonoester bond which is
close to protein carrier. The complementary ion gives is represented in the CAD mass
spectrum with an abundant peak at m/z 1041.4 (charge state +15). The other ion (m/z
256) is originated from the cleavage of phosphonoester bond which is close to adefovir.
Its corresponding complementary fragments at high m/z region are m/z 977.5 (+16) and
1042.6 (+15). Ion peaks [i.e. 961.5 (+16) and 1024.4 (+15)] representing conjugates which
undergo double 255 Da loss were observed during the fragmentation (see Figure
Appendix C1). Besides those fragmentations which occur on protein linked PMEApa, CAD
also induces cleavages of polypeptide amide bonds, providing location information of the
drug conjugations (see Figure Appendix C1, C3 and C4). Although phosphonoester bonds
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in protein conjugated PMEApa are labile in the gas phase and probably undergo
dissociation

prior

to

peptide

fragmentation,

the

resultant

residues

(i.e.

phosphonoacetylated peptides or their dehydrolyzed form) (see their structures in Figure
Appendix C2) can be used to map conjugation sites of PMEApa. The presence of Hb (α)derived peptide fragments in the CAD mass spectrum of the Hb/PMEA conjugate is not
surprising since the precursor ion represents Hb (α)/(PA)2(PMEA)2. What is surprising is
that the majority of the peptide fragments are derived from Hb (β). This can be explained
by that the mass isolation includes Hb (β)/(PA)4(PMEA)2 (m/z 993, charge state +17) which
has very close m/z value with Hb (α)/(PA)2(PMEA)2 (m/z 993.5, charge state +16). Analysis
of those peptide fragments indicates that N-terminal primary amine-containing residues
such as V1, K7, K11 and K16 on Hb (α) and V1, K8 and K17 on Hb (β) are probably the
conjugation sites in this reaction. Conjugation at those residues on Hb are not that
surprising because some of them (including βV1, αV1, βK8 and αK11) have been evaluated
to have very high reactivity in Hb PEGylation (Hu, T. Biochem. J., 392, 555-564 (2005)).
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Figure Appendix C1. Mass spectrum of fragment ions produced by collisional
activation of 1:2 Hb(α)/PMEA conjugate (m/z 993.5). The diagram shows the structure
of observed fragment ions.
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Figure Appendix C2. Structures and labels of PMEApa linked peptides and their CAD
induced residues.
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Figure Appendix C3. Zoomed view (m/z 650-950) of mass spectrum of fragment ions
produced by collisional activation of 1:2 Hb(α)/PMEA conjugate (m/z 993.5).
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Figure Appendix C4. Zoomed view (m/z 1050-1400) of mass spectrum of fragment
ions produced by collisional activation of 1:2 Hb(α)/PMEA conjugate (m/z 993.5).
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Figure Appendix C5. CAD fragmentation map derived from data shown in Figure
Appendix C1, C3 and C4.
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APPENDIX D
PREPARATION OF P-CYMENE RUTHENIUM LABELED ADEFOVIR PHOSPHONOACETATE
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Method. Preparation of ruthenium labeled adefovir phosphonoacetate is shown in
Figure of Summary and Future Direction. 11 mg dichloro(p-cymene)ruthenium(II) dimer
(0.018 mmol) was dissolved in acetone (dark brown), followed by addition of 18.8 mg
silver trifluoromethanesulfonate (0.072 mmol). After 30 min stirring, light yellow
precipitates (i.e. silver chloride) was centrifuged down and the supernatant (orange) was
placed in another glass vial to interact with 14.4 mg adefovir phosphonoacetate (0.018
mmol). After 4-hour incubation (stirring), brown precipitates were collected and dissolved
in water for MS analysis.
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APPENDIX E
DETERMINATION OF LIMIT OF DETECTION AND LIMIT OF QUANTITATION IN
QUANTITATION OF GA LABELED HEMOGLOBIN HAPTOGLOBIN COMPLEX USING ICPMS
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Method: Quantitation of gallium in serum samples spiked with Hp∙HbGa was carried
out using NexION 300X (PerkinElmer, Waltham, MA) ICP mass spectrometer. The kinetic
energy discrimination (KED) mode was used to reduce polyatomic interference. Gallium
quantitation in serum was based on an external calibration curve obtained with a
standard solutions of Ga (0.01 to 1 μg L-1), which also contained Rh (1 μg L-1) as the internal
standard. Intensities of ionic signals at m/z 69 (69Ga), 71 (71Ga) and 103 (103Rh) were used
to calculate the

69Ga/103Rh

and

71Ga/103Rh

ratios, from which calibration curves were

constructed. Rh was also added to all serum samples (to a final concentration of 1 μg L-1)
following their overnight digestion at 37 OC in a mixture of nitric acid (49%) and hydrogen
peroxide (7%). The limit of detection (LOD) of this method was calculated using equation
as follows:
∑𝑖𝑖(𝑦𝑦𝑦𝑦−𝒚𝒚𝒊𝒊)2

3

LODx= 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 × �

𝑛𝑛−2

yi is measured value; darkened yi is fitted value on the calibration curve.
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Figure Appendix E. Evaluation of the feasibility of quantitation based on Ga
isotopes based on external calibration curves obtained with Rh as the internal
standard. Intensities of ionic signals at m/z 69 (69Ga), 71 (71Ga) and 103 (103Rh)
are used to calculate the 69Ga/103Rh and 71Ga/103Rh ratios, from which calibration
curves are constructed. The two calibration curves (69Ga/103Rh and 71Ga/103Rh)
have linear regression coefficients r2 of 0.995 and 0.994, respectively. The limit
of detection (LOD) for Ga is calculated to be 0.03 ppb, the limit of quantitation is
calculated to be 0.1 ppb using the commonly accepted algorithms (Miller, J.N.,
Miller, J.C. Statistics and Chemometrics for Analytical Chemistry, 6th edition.
Pearson Education Limited, Essex, UK, 2010). These LOD and LOQ numbers
correspond to Hp∙HbGa concentration levels 0.12 nM and 0.41 nM. Assuming the
total labeling ratio is 3.5:1.
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APPENDIX F
CATION EXCHANGE CHROMATOGRAM OF LYSOZYME ADEFOVIR CONJUGATE
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Method: IXC (cation exchange) was performed on Agilent 1100 (Agilent, Santa Clara,
CA) liquid chromatograph equipped with a 2.1 mm × 100 mm PolyCAT A (PolyLC Inc.,
Columbia, MD) weak cation-exchange column (particle size of 5 μm and pore size of 300
Å). Ammonium acetate at pH 7.0 was used for MS-compatible gradient elution (100 mM
in mobile phase A and 1 M mobile phase B). The flow rate was maintained at 0.1 mL/min,
and the linear gradient ran from 0% to 60% mobile phase B during a 60 min time interval.
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Figure Appendix F. UV chromatogram (cation exchange) of Lz/PMEA conjugate
produced from pH 6.8.
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